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ABSTRACT 
 
 
SCOTT PHILIP NICHOLS: Tissue Integration and Antimicrobial Effects of Surface-derived 
Nitric Oxide Release 
(Under the direction of Professor Mark H. Schoenfisch) 
 
 
 The analytical performance of glucose sensors is inhibited by the host’s foreign body 
response (FBR) and risk of bacterial infection. To date, no one strategy has circumvented the 
physiological reactions to implanted materials. Nitric oxide (NO) is an endogenously 
produced free radical that acts to initiate events in the FBR and fight bacterial infection. 
Herein, the potential of NO-releasing surfaces to both mitigate the FBR and bacterial 
invasion is described. 
 Evaluation of the performance of NO-releasing surfaces to improve glucose sensor 
performance in vivo was carried out through imparting NO release to microdialysis probes. 
Perfusion of saturated NO solutions through implanted probes delivered a constant flux of 
162 pmol cm-2 s-1 delivering 4.6 µmol cm-2 NO each day. The NO-releasing probes 
recovered significantly greater concentrations of glucose after 7 d of implantation versus 
controls. Histological analysis revealed a thinner collagen capsule and decreased 
inflammation adjacent to NO-releasing probes.  
 To investigate the necessary NO-release properties to achieve the observed 
histological benefits, NO-releasing polyurethane-coated wires were implanted into a porcine 
model for up to 6 weeks. Polyurethanes were doped with small molecules or nanoparticles to 
alter the NO release kinetics, fluxes, and total payloads. Materials with a NO-release duration 
iii 
 
of 14 d and large NO payload (9.3 µmol cm-2) were most effective at decreasing the collagen 
encapsulation and inflammation adjacent to the implants. Inflammation was only modulated 
during active NO release from the implant. 
 While modulation of the FBR is essential for the development of glucose sensors, 
infection by bacteria is a constant threat. Biomaterial-associated infections most commonly 
begin through adhesion to the implanted material. Therefore, evaluation of the anti-adhesive 
properties of NO-releasing surfaces was undertaken by examining the adhesion of six 
bacterial strains to a wide range of NO fluxes (0.5–50 pmol cm-2 s-1). An average NO flux 
between 50 pmol cm-2 s-1 reduced surface coverage of all strains by >80% over 1 h. Further, 
after incubation of adhered bacteria in bacteriostatic conditions for 24 h, large surface-
derived NO payloads (1.7 µmol cm-2) decreased viability of adhered bacteria by ≥85%. 
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Chapter 1: 
Opportunities in Nitric Oxide Release Materials: Towards More Biocompatible Glucose 
Sensors 
1.1. Difficulties with implementation of implantable glucose sensors 
 Diabetes is a common disease afflicting 25.8 million people in the United States 
alone.
1
 The disease arises from either deficiencies in the production of or response to insulin, 
a down-regulator of blood glucose. Therefore, diabetic patients must carefully monitor their 
glucose levels and make suitable adjustments in insulin injections or food intake. 
Mismanagement of glucose levels can lead to dire consequences including ulcers, 
amputations, and even death. Currently, long-term self-monitoring of glucose levels is 
recommended through the finger prick method which consists of piercing a finger with a 
needle and directly testing the blood.
2
 While this method is useful and accurate, there are 
limitations with patient compliance and the often too little information (snapshot) provided 
regarding blood glucose levels throughout the day. A single point does not reveal the trend of 
the blood glucose over time and therefore fosters misinterpretation and subsequent 
misdiagnosis by the user. Due to these concerns, continuous glucose monitoring (CGM) 
devices have been sought.
3, 4
 Such systems would allow for real-time information on glucose 
concentrations and presumably improve patient compliance. For example, CGM devices 
would predict glucose levels and ultimately be connectable to an artificial pancreas to 
automatically control glucose levels. 
2 
 
 Though the benefits of an implantable glucose sensor are quite clear, CGM devices 
are limited by deficiencies in their biocompatibility. Currently, CGM devices approved by 
the FDA to work for 5–7 d and are currently intended only to assist a patient in 
understanding their glucose level trends.
5
 These sensors are useful tools, but cannot replace 
finger-prick methods for extended glucose monitoring and often require frequent calibration 
(via finger pricks). Implantable glucose sensors are primarily limited by the host’s foreign 
body response (FBR). Significant research has explored methods to increase the 
biocompatibility of in vivo sensors to extend the analytical functionality and provide reliable 
and accurate glucose levels.
6
 
1.2. Biocompatibility of implanted materials 
 Many biomedical implants are currently approved for implantation into the human 
body. While these biomedical materials are routinely implemented, limitations in 
functionality, safety, and lifetime persist due to the host tissue response, termed the foreign 
body response (FBR). Even materials considered to be biocompatible elicit a weak FBR, 
forming a thin, avascular encapsulation which prevents full integration of the implant into the 
surrounding native tissue. Despite the implementation of aseptic procedures, infection 
resulting from implanted biomaterials is also commonplace. An implant-associated infection 
necessitates device removal with large risk for severe complications including amputation or 
even death. Both isolation of glucose sensors through the FBR and bacterial colonization of 
the implant site can lead to erratic sensor performance. Thus, significant research has focused 
on methods to promote the development of native host tissue around an implant. 
 1.2.1. The foreign body response and sensor performance.  As shown in Figure 1.1, 
the FBR initiates upon the insertion of almost any material into subcutaneous tissue, starting  
3 
 
 
 Figure 1.1. The progression of the foreign body response (FBR) with time. (A) Initially, the 
biomaterial is implanted into injured native tissue composed of blood vessels, proteins and 
cells. (B) Proteins and cells adhere to the surface and the adhered cells release 
chemoattractants and cytokines to direct the FBR. (C) At 1–2 weeks, macrophages have 
fused into foreign body giant cells (FBGCs) and leukocytes have deposited an organized 
collagen encapsulation sequestering the material from the native tissue and blood vessels. 
4 
 
 with the creation of a wound and the wound healing cascade.
7, 8
 Instantaneously, proteins 
adhere to the biomaterial surface in a process referred to as biofouling.
8, 9
 The initial protein 
adsorption is an integral part of the overall FBR as the ensuing interface promotes the 
adhesion of inflammatory cells that subsequently stimulates blood clotting and the 
development of a provisional matrix.
9
 As part of the FBR, macrophages, monocytes, mast 
cells, and fibroblasts are recruited to the implant site to initiate clearance of the foreign body 
by releasing chemokines and cytokines.
7, 8
 The concentrations and types of mediators 
released elicit further cell recruitment and ultimately phagocytosis
10
 as the body attempts to 
digest the implant. This process can result in a local pH’s dropping as low as 3.6 and 
disrupting biosensor performance as the activity of GOx is pH dependent.
11
 While preventing 
all macrophage migration and subsequent phagocytosis at a wound (glucose sensor) is 
unlikely, the activation state (i.e., M1 or M2) of the macrophage may influence the overall 
FBR. Indeed, macrophages serve three primary functions in the body: host defense, wound 
healing, and immune regulation.
12
 Since macrophages are vital for the wound-healing 
process that results from an injury, the phenotype of the cells present at an implant, rather 
than their concentration, is now believed to be a better indicator of tissue response.
13
 As the 
FBR progresses, frustrated phagocytosis from activated macrophages will lead to the fusion 
of macrophages into foreign body giant cells (FBGCs) that attempt to further breakdown the 
implant.
11, 14-16
 For example, FBGC formation on polyurethanes has been shown to promote 
cracking of the underlying biomaterial.
14
 After one to two weeks, inflammatory cells deposit 
a collagen matrix that sequesters the implant from the native tissue. This collagen 
encapsulation lacks the microvasculature of native tissue.
17
 As blood vessels are the primary 
source of glucose, such encapsulation hinders accurate measurements of blood glucose. The 
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extent of capsule development is dependent on all other preceding components of the FBR, 
including protein adhesion, cell activation, and cytokine signaling. The collagen 
encapsulation will persist for the lifetime of the device, negatively impacting sensor 
performance with respect to sensitivity and response (e.g., lag times). 
 While the individual effects of each step in the FBR on glucose sensor performance 
have been postulated, actual outcomes are more difficult to determine. Researchers have long 
sought to untangle the complexities that connect various events in the FBR with tissue 
integration and glucose sensor performance, as this knowledge could lead to the development 
of materials that address the specific tissue responses that most severely inhibit sensor 
performance. 
 The synthesis of antifouling materials has evolved to be a common strategy for 
improving glucose sensor functionality as the initial adhesion of proteins and cells onto a 
glucose sensor mitigates sensor performance.
18, 19
 Among the earliest reports describing 
reduced analytical performance, Thomé-Duret et al. implanted polyurethane-coated glucose 
biosensors to quantify changes in analytical sensitivity.
18
 Soon after implantation, the sensors 
were explanted and tested ex vivo.
18
 While the immediately explanted sensors had glucose 
sensitivities similar to those analyzed in vivo, response to glucose improved after rinsing, 
albeit not to pre-implantation levels.
18
 Nevertheless, this reversibility indicated that the 
process was passive and likely caused by biofouling on the sensor.
18
  Proteomic analysis 
revealed that the majority of the biofouling proteins on the sensor membrane were fragments 
<15 kDa.
20, 21
 In contrast, Wisniewski et al. evaluated the impact of collagen encapsulation 
versus biofouling using microdialysis probes and found biofouling effects to actually be 
minimal.
22
 Specifically, the resistance to mass transfer of analyte (i.e., glucose) caused by the 
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tissue over both short- (3 h) and long-term (8 d) implantation periods were typically 3 to 5 
times greater than that caused by biofouling of the probes, regardless of implantation 
period.
22
 The observed biofouling was found to have only relatively small direct effects on 
the overall resistance and glucose extraction efficiency.
22
 It is important to note however that 
biofouling of proteins and cells at the sensor-tissue interface will also affect the tissue 
response to a biomaterial as will the composition of the polymers used to fabricate the 
sensors and dialysis probes. 
 Following protein adhesion/biofouling, the FBR proceed with inflammatory cells 
responding to the injury, initiating a more profound immune response to the device. Klueh et 
al. reported on the effects of mast cells, regulators of inflammation.
23
 Both mast cell-
sufficient and -deficient mice were implanted with subcutaneous glucose sensors for 28 days. 
During this period, glucose sensor performance in mast cell-sufficient mice was erratic with 
temporary response loss occurring within the first 3 weeks. Sensor performance in mast cell-
deficient mice was markedly better with reliable sensor function throughout the 28-day 
period.
23
 Histology samples from both experimental groups confirmed that the mast cell-
deficient mice exhibited reduced fibrosis and inflammation at the implantation site. To 
further confirm the effect of mast cells on glucose sensor performance, 10
4–105 mast cells 
were injected at the implant site.
23
 While glucose sensor performance recovered soon after 
injection (~15 min), the sensor response to glucose decreased after 1–2 days, further 
indicating a link between mast cell action and erratic glucose sensor performance.
23
 
 The most characteristic outcome of the FBR is collagen encapsulation around the 
foreign device. Early investigations of capsules formed around sensors focused on the 
influence of the capsule on glucose diffusion from native tissue. For example, Sharkawy and 
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coworkers implanted non-porous polyvinyl alcohol (PVA) and stainless steel cages into the 
subcutaneous tissue of rats.
24
 Upon careful explantation of the collagen capsules, the 
diffusion of sodium fluorescein (376 g/mol) through the capsule was quantified and used to 
model small analyte transport.
24
 Diffusion of the fluorescein through the explanted capsules 
was ~50% that of normal (i.e., subcutaneous) tissue.
24
 Sensor lag times for native tissue was 
estimated at ~20 min, but tripled when modeled with decreased diffusion due to a capsule.
24
 
Interestingly, empirical data suggests that lag times range from 10–15 min in vivo, indicating 
the integral function of angiogenesis in early granulation tissue. In subsequent experiments, 
Dungel et al. examined the effects of encapsulation on sensitivity by evaluation the response 
of glucose sensors inserted into polyvinyl alcohol sponges implanted in rats.
25
 The glucose 
sensitivity in vivo peaked at day 7, but then decreased for the duration of the study.
25
 Glucose 
sensitivity correlated well with the collagen encapsulation of the sponges with thicker 
collagen resulting in greater sensitivity loss.
25
 Koschwanez et al. investigated the effects of 
vascularity on glucose sensor performance in real-time by using an implanted optical window 
over the sensor, microscopy, and laser Doppler flowmetry.
26
 The vessel length and perfusion 
of the vasculature increased during the implantation period (i.e., 14 d). Despite such 
increases in vasculature, the sensitivity of the sensor did not increase indicating that 
angiogenesis is not the only factor in assessing the biocompatibility of CGM sensors.
26
 
 Mathematical models and simulations of implantable glucose sensors have further 
helped understand how the processes of the FBR may affect glucose sensor performance. 
Simulations of glucose concentration oscillations by Jablecki and Gough concluded that 
increases in mass transfer would increase lag and could potentially decrease the magnitude 
and differences when fluctuating between high and low glucose sensor signals.
27
 While this 
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conclusion is important for sensor design, the increases to mass transfer were not attributed 
to any specific part of the FBR and could originate from collagen capsule thickness, blood 
vessel density, or other unanticipated factors. To consider major tissue reactions individually, 
Novak and coworkers used a mathematical model to examine FBR effects on glucose sensor 
performance.
28
 Using previous histology data, five parameters (i.e., angiogenesis, cellular 
glucose consumption, capsule thickness, capsule diffusion coefficient, and capsule porosity) 
were used to design a mathematical model that mimicked glucose diffusion from capillaries 
to a glucose sensor in order to simulate the effect on sensor lag time and attenuation.
28
 The 
mathematical model treated vessels as sources of glucose and inflammatory cells as glucose 
sinks, while the encapsulation properties acted to impede the diffusion of glucose.
28
 Changes 
in cellular glucose uptake and the capsule diffusion coefficient of glucose had little effect on 
simulated sensor performance.
28
 The model was ultimately used to conclude that collagen 
capsule thickness, a common histological parameter, was the primary source of sensor lag 
time with little impact on sensor response attenuation.
28
 The positive correlation between lag 
time and capsule thickness supported the models described above.
24, 27, 28
 The two greatest 
factors in reducing sensor attenuation were a low capsule density and high degree of 
angiogenesis.
28
 While these are only mathematical models, the results do identify the 
histological parameters of key interest when assessing the biocompatibility of materials for 
glucose sensors. 
 1.2.2. Bacterial infection. Even when aseptic methods are utilized, incidences of 
biomaterial-associated infections originating from either endogenous or exogenous bacterial 
sources remain. Approximately 5% of surgeries result in the development of an infection, 
regardless of the implantation of a device.
29
 The implantation of a device creates a surface on 
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which bacteria to colonize and proliferate.
30
 Current biomaterials do little to prevent implant-
associated infections. Furthermore, the administration of systemic antibiotics, the leading 
treatment for infections, has lead to a dwindling efficacy and the emergence of antibiotic-
resistant bacterial strains. The development of an implant-associated infection necessitates 
the removal of the device and can lead to more serious complications, including death. With 
the rise in biomedical implant usage and antibiotic-resistant strains of bacteria, the number of 
implant-associated infections will likely increase. 
 Implanted biomaterials provide conditions that promote bacterial colonization. Upon 
implantation, either the native tissue integrates with the implanted material or bacteria adhere 
to the surface and colonize.
31
 Bacteria are most likely to adhere and colonize during the 6 h 
directly following implantation.
32
 This colonization can result in the formation of a persistent 
biofilm which is difficult to fully eradicate. Killing of bacteria comprising a biofilm versus 
their planktonic counterparts requires up to 1000x increased doses of antibiotics.
33, 34
 Early 
killing and prevention of adhesion would decrease the susceptibility of implantable materials 
to bacterial infections. Currently, many clinically approved materials do not sufficiently 
prevent bacterial adhesion and biofilm formation on their surface.
35
  
1.3. Animal models for evaluating biocompatibility 
 When implanting in vivo, researchers often use rodent models (e.g., mouse
36
 or rat
37, 
38
) models to assess in vivo biocompatibility and/or glucose sensor functionality, though 
others (e.g., pigs,
39
 dogs,
40
 and chimpanzees
41
) are used as well. Such animal models are time 
and labor intensive while requiring surgical skills. Although an avian chorioallantoic 
membrane has been proposed as an alternative model for testing biomaterials with obvious 
expense benefits, long-term studies (i.e., >2 weeks) are not feasible.
42, 43
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 Unfortunately, the degree to which animal models accurately predict the FBR and 
analytical performance of glucose sensors in humans has come under scrutiny. For example, 
Wisniewski et al. compared the dialysate concentrations of glucose, pyruvate, lactate, 
glycerol, and urea at a microdialysis probe-tissue interface implanted in the subcutaneous 
space of both rats and humans to evaluate the validity of the cross-species relationship.
44
 The 
dialysate concentrations were significantly different for all metabolites in rats and humans 
throughout the first 6 days of the experiment, with the exception of glycerol on day 0.
44
 
Additionally, the ratio of the glucose concentration in the dialysate to that in blood were 
significantly different between rats and humans indicating differences in the relative glucose 
availability in the tissue surrounding an implanted device.
44
 Histology samplings from human 
subcutaneous tissue showed a greater concentration of adipose cells while rat tissue was 
characterized with larger amounts of collagen.
44
 Taken together, these results necessitate 
careful consideration and caution when extrapolating results from animal models to humans. 
 In addition to differences between species, one parameter that is not often considered 
is the differential healing response in diabetic versus healthy (i.e., non-diabetic) patients. 
Diabetics typically suffer from delayed and diminished wound healing.
45
 It is currently not 
known how such physiology affects the FBR and subsequent sensor performance. In a key 
study, Gertissen et al. investigated the differences in the FBR between diabetic and non-
diabetic rabbits to percutaneous and subcutaneous materials.
46
 Histological analysis revealed 
delayed neovascularization and less matrix production in the diabetic rabbits that clearly 
could influence glucose sensor performance.
46
 Due to such important histological 
differences, diabetic animals should likely be used to better simulate tissue response and 
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characteristics of diabetic patients. Of note, many diabetic models are available including 
both genetic and chemically-induced.
47
 
1.4. Nitric oxide 
 The implantation of a biosensor into a host raises concerns of a lack of 
biocompatibility (i.e., collagen encapsulation and inflammation) and the potential to promote 
bacterial colonization and subsequent infection. Thus, a strategy to address these primary 
concerns has been the release of nitric oxide (NO) from implantable surfaces. 
 Since NO was identified as the endothelial derived relaxation factor (EDRF) in 1986, 
there has been extensive research into the many functions of NO in the body.
48
 Nitric oxide is 
an endogenously produced free radical synthesized from L-arginine by one of three isoforms 
of nitric oxide synthase (NOS): neuronal NOS (nNOS), endothelial NOS (eNOS), and 
inducible NOS (iNOS).
49
 The nNOS isoform is present in many tissues outside the brain 
including skeletal muscle and islet cells while eNOS is present almost exclusively in the 
endothelium.
50
 These two isoforms create low concentrations (i.e., nM) of NO. Inducible 
NOS can be expressed in any cell when exposed to certain cytokines or lipopolysaccharide 
(LPS) and is often expressed by macrophages in response to bacterial infection or 
inflammation to synthesize µM concentrations of NO.
50
 
 1.4.1. Roles in the foreign body response. While the mechanisms have not been 
completely elucidated, NO is known to control many functions of the FBR that may affect 
implantable glucose sensors. Nitric oxide has been indicated as an angiogenic signaling 
molecule,
51
 and there are several reports of NO up-regulating VEGF production and thereby 
increasing blood vessel growth.
52
  Furthermore, VEGF acts to up-regulate eNOS expression 
thus inducing vasodilation. The angiogenic behavior exhibited by NO would be helpful for 
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avoiding the typical avascular encapsulation that plagues successful glucose sensor 
performance. Additionally, NO is believed to control inflammatory cell recruitment in the 
early stages of the FBR. Localized NO may cause nitrosation of proteins and down-regulate 
pro-inflammatory cytokine expression (e.g., macrophage chemoattractant protein-1).
53
 
Furthermore, NO has been reported to reduce leukocyte adhesion at elevated concentrations 
and could thereby prevent localization of inflammatory cells at an implanted glucose 
sensor.
54
 The reduction of leukocytes at the implant aids in the reduction of inflammation and 
subsequent FBR at the wound site. 
 1.4.2. Antibacterial properties. Macrophages synthesize and release endogenous NO 
at concentrations >1 µM in response to bacterial infections.
55, 56
 Thus, significant research 
efforts are focused on harnessing the antimicrobial properties of NO. As a free radical, NO is 
very reactive and can cause damage to cells both directly and indirectly through resulting 
byproducts (e.g., N2O3). At the exterior of a bacterial cell, NO may react with endogenous 
superoxide to produce peroxynitrite, which is capable of damaging the cell membrane 
through lipid peroxidation.
57
 Observations via atomic force microscopy confirm that NO 
release compromises the bacteria membrane.
58
 Inside the cell, NO can nitrosate proteins and 
cause strand breaks or base changes in DNA.
59
 Unlike many antibiotics, NO acts through 
multiple killing mechanisms which not only increases the probability of bacterial cell death 
but also significantly decreases the probability of bacterial resistance evolving.
60
 
 1.4.3. Controllable delivery of nitric oxide. Given the roles of NO in the immune 
response, favorable tissue reactions to NO-releasing substrates in vivo are expected, 
however, due to its gaseous nature, direct delivery of NO in vivo is not trivial. To achieve in 
vivo release, NO donors have been synthesized as a method to store NO that may be released 
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upon some trigger.
61, 62
 The most commonly studied donors for implant-derived in vivo NO 
delivery are N-diazeniumdiolates and S-nitrosothiols (Figure 1.2). N-diazeniumdiolates are 
formed on secondary amines upon exposure to NO in basic conditions.
63
 In the presence of a 
proton source (e.g., water), the N-diazeniumdiolate decomposes to release two molecules of 
NO, regenerating the parent amine in the process.
63
 The rate of release from these moieties is 
therefore dependent on the pH, ionic strength, and surrounding chemical environment.
63, 64
 S-
nitrosothiols are formed on thiols exposed to nitrosating conditions (e.g., acidified nitrite) 
and degrade when exposed to light, copper (I), or heat, releasing one NO molecule per 
thiol.
65
 Similar to N-diazeniumdiolates, the NO release kinetics from S-nitrosothiols are 
dependent on the NO donor chemical structure. The utility of NO donors for improving 
biocompatibility was initially investigated by incorporating low molecular weight (LMW) 
NO donors of N-diazeniumdiolates (e.g., N-diazeniumdiolated L-proline) and S-nitrosothiols 
(e.g., S-nitrosoglutathione) into biomaterials to impart NO release capabilities.
66-68
 
Limitations of LMW NO donors include short release kinetics and cytotoxicity. More 
recently, there have been efforts to synthesize novel NO donors to both alter NO release 
kinetics and reduce mammalian cell cytotoxicity. To this end, macromolecular scaffolds have 
been designed including silica nanoparticles
69-71
 and silica xerogels.
72-79
 Nanoparticles and 
xerogels materials can be doped into polymer scaffolds or used as coatings, respectively, 
permitting NO release from any implanted material. These materials can be used to evaluate 
the effects of NO release in vivo. 
1.5. Evaluating the host response via microdialysis 
 Microdialysis is a sampling technique in which a fluid is perfused through a probe 
with a semi-permeable membrane where diffusion between the perfusate and external
14 
 
 
Figure 1.2. Two major nitric oxide donors (i.e., N-diazeniumdiolates and S-nitrosothiols) and 
their primary decomposition mechanisms. 
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medium occurs and is collected as a dialysate. The extraction efficiency (EE) is obtained by 
comparing the concentrations of a given analyte in the perfusate (Cp), dialysate (Cd), and 
external medium (Ce) (Equation 1.1).  The EE can be further related through the Bungay-
Morrison-Dedrick equation to resistances to mass transfer of the dialysate (Rd), membrane 
(Rm), and external medium (Re), as well as the flow rate of the perfusate (Qd) (Equation 
1.1).
80, 81
 When implemented in vivo, resistances in the external medium may be the result of 
biofouling or other tissue effects (e.g., collagen encapsulation). Therefore, evaluating the EE 
over time offers a method to determine the biocompatibility of the probe material. This 
method is particularly useful for investigating glucose sensors as the resistances to mass 
transfer also offers insight into the effective lag time of a sensor. While microdialysis allows 
for simple temporal testing of materials, the materials tested are limited to semi-permeable 
membranes. 
 Similar to implantable biosensors, microdialysis probes suffer from diminished 
analyte recovery over time. This reduction in analyte recovery is associated with increased 
resistances to mass transfer. Wisniewski et al. examined the effect of microdialysis 
membrane composition on the EE of glucose in rat subcutaneous tissue.
22
 Poly(ether sulfone) 
(PES), polycarbonate (PC), and polyacyrlonitrile (PAN) microdialysis probe membrane 
compositions were investigated  and glucose recovery was measured at 0, 2, 5, and 8 d post-
implantation. The PES membranes exhibited a significant reduction in glucose recovery at 2 
d post-implant. All probe compositions experienced diminished glucose recovery after 8 d of 
implantation. Later investigation by Mou et al. examined recovery of multiple analytes over 
time in rat subcutaneous tissue using PES and PC microdialysis probes.
82
 No significant 
differences were observed in glucose recovery in vivo between PES and PC membranes. The 
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Equation 1.1. The Bungay-Morrison-Dedrick equation relating extraction efficiency (EE) to 
flow rate (Qd) and resistances to mass transfer (R). 
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EE of perfused vitamin B12 and recovered glucose by the microdialysis probes after 12 d 
were reduced by 71.4 and 71.1%, respectively. 
 Researchers have attempted to improve glucose recovery of microdialysis probes by 
implementing more biocompatible materials and releasing anti-inflammatory molecules. 
Norton et al. investigated the EE of glucose in rat subcutaneous tissue using both bare 
microdialysis probes and those with an overlaying hydrogel interface.
83
 The additional 
diffusion of glucose through the hydrogels resulted in an increase in resistance to mass 
transfer in vitro. When tested in vivo, the improved biocompatibility provided by the 
hydrogel caused only non-significant improvements in tissue integration (reduction in 
resistance to mass transfer of glucose) during the 8 d implantation. Later studies from Mou et 
al. investigated the effect of actively releasing monocyte chemoattractant protein-1 (MCP-1; 
a pro-inflammatory drug) and dexamethasone (DX; an anti-inflammatory drug) on the 
recovery of glucose in rat subcutaneous tissue.
84
 The delivery of MCP-1 resulted in a 
collagen capsule that was 2x the thickness of control probes after 10 d. In contrast, the DX-
releasing probes had very fragile collagen capsules due to the low degree of fibrosis in the 
adjacent tissue and could not be processed for histological analysis. The increased FBR to the 
MCP-1-releasing probes caused a significant decrease in glucose recovery versus controls 7 d 
post-implant. However, even with the observed fragile collagen capsules adjacent to DX-
releasing probes, no significant differences in glucose recovery were observed over versus 
controls over the 10 d experiment. However, the DX-releasing probes were functional 2 d 
longer than control probes, indicating a potential benefit to the anti-inflammatory molecule. 
 Despite the slight non-significant advantages, the previous studies found that surface 
modifications with hydrogels and release of anti-inflammatory molecules were incapable of 
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improving the recovery of glucose in vivo. As NO release has been observed to improve 
angiogenesis while decreasing collagen encapsulation and inflammation, delivery of the 
molecule may be able to minimize the in vivo resistances to mass transfer of glucose caused 
by the FBR. 
1.6. Histological analysis of NO-releasing materials 
 Macromolecular NO donors have been implemented to investigate the potentially 
positive tissue reactions to NO-releasing materials. Hetrick et al. coated 40% N-(6-
aminohexyl)aminopropyltrimethoxysilane (AHAP3) balance isobutyltrimethoxysilane 
(BTMOS) xerogels onto square silicon rubber implants and chemically modified them with 
N-diazeniumdiolates.
85
 The substrates were capable of delivering a NO payload of 1.3 µmol 
cm
-2
 over 3 d.
85
 The materials were then implanted into rat subcutaneous tissue for 1, 3, or 6 
weeks and histology of the surrounding tissue was examined.
85
 The chronic collagen 
encapsulation was reduced at 3 and 6 weeks by ~20–25% compared to non-NO-releasing 
xerogels.
85
 In addition to the reduced capsule thickness, the chronic immune response (i.e., 3 
and 6 weeks) was reduced while angiogenesis was enhanced at 1 and 3 weeks.
85
 Indeed, 
these results indicate a possible long-term benefit for NO-releasing glucose sensors. A 
mitigated immune response could result in reductions in local glucose consumption and 
reactive oxygen species, while angiogenesis observed could significantly impact the 
observed sensitivity of a glucose sensor and decrease lag time by reducing the distance from 
glucose source to implant surface.  
 To investigate short-term effects of NO release from implants on the FBR, Gifford et 
al. doped (Z)-1-[N-methyl-N-[6-(N-butylammoniohexyl)amino]]-diazen-1-ium-1,2-diolate 
(DBHD/NO) into a polyurethane and polydimethylsiloxane coating which was capable of 
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releasing NO for 18 h.
21
 The materials were implanted percutaneously into rats for 3 d.
21
 
Subsequent histological analysis of the tissue revealed a decrease in inflammation at 24 h, 
but not 48 h.
21
 The anti-inflammatory benefits correlated well with the NO release duration 
indicating that the observed benefits may only persist for the duration of NO release, in 
contrast to observations by Hetrick et al. which observed long-term reductions in 
inflammation.
21, 85
 Such results demonstrate the potential of NO as a mediator of the FBR for 
glucose sensors.  
 These studies each focused only on a single NO-releasing material for evaluating the 
effect on the FBR. Therefore, the differences observed may not be optimal and the proper 
release of NO from an implantable biomaterial could further enhance tissue integration. 
Nitric oxide release properties (e.g., maximum NO flux, NO release duration, total NO 
release) likely have a significant impact, but the role of each parameters is largely unknown. 
Furthermore, these studies have concentrated on rodent models of the FBR, which while 
useful, are not the best model of humans. Porcine models may better mimic the response in a 
human and provide insight into the necessary NO release properties to improve tissue 
integration.
86
 
1.7. Effects of exogenous NO on bacterial adhesion and viability 
 In addition to NO’s role as an antibacterial agent, it reduces bacterial adhesion which 
can subsequently inhibit bacterial colonization.
76, 78, 87
 Inhibiting initial adhesion of bacteria 
is critical for preventing implant associated infections.
88
 Early experiments by Nablo et al. 
revealed that under static conditions, NO-releasing xerogels provided a flux-dependent 
reduction in P. aeruginosa adhesion. An initial NO flux of 5 pmol cm
-2
 s
-1
 reduced adhesion 
by 25%, while the largest NO flux investigated (~32 pmol cm
-2
 s
-1
) inhibited adhesion by 
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85%. Interestingly, P. mirabilis adhesion was also reduced by NO release, but not in a NO 
flux-dependent manner. Indeed, all NO fluxes examined (ranging from ~10–32 pmol cm-2 s-
1
) reduced adhesion of P. mirabilis by ~50% to PVC-coated xerogels.
89
 Charville et al. 
examined the effects of NO release with fibrinogen biofouling to more closely mimic in vivo 
conditions. Specifically, S. aureus was found to adhere ~5.3x more to poly(vinyl chloride) 
(PVC) surfaces with adsorbed fibrinogen than PVC alone while E. coli and S. epidermidis 
exhibited modest enhancements (1.2–1.8x). Even while bacterial adhesion was promoted by 
fibrinogen adsorption to the surface, NO release reduced bacterial adhesion of S. aureus and 
E. coli by 96 and 88%, respectively.
90
 NO-releasing xerogels exhibited a flux-dependent 
reduction in bacterial adhesion. Interestingly, S. epidermidis was found to have greater 
surface coverage even with relatively large NO fluxes (48% reduction at 30 pmol cm
-2
 s
-1
) 
and overall was less susceptible to NO-induced reductions in adhesion. 
 Under flow conditions, substrates that release ~21 pmol cm
-2
 s
-1
 have been shown to 
reduce adhesion of P. aeruginosa by 65% relative to controls.
73
 In the same study, Hetrick 
and Schoenfisch examined the viability of adhered P. aeruginosa to varying payloads of NO 
in static conditions (i.e., phosphate buffered saline). After 16 h of incubation, a NO payload 
of 750 nmol cm
-2
 reduced viability of P. aeruginosa by 96% compared to substrates that 
released only 25 nmol cm
-2
, though the viability was not compared to substrates lacking NO 
release. These results exemplified both the ability for NO to decrease bacterial adhesion and 
a NO payload-dependent killing of bacteria. 
 Seabra et al. examined the potential of NO-releasing catheters to reduce bacterial 
adhesion by mixing poly(sulfhydrylated polyester)s (PSPEs) with polymethylmethacrylate 
(PMMA) to create a solid polymer. The polymers were nitrosated and upon exposure to 10
5
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CFU of either S. aureus and P. aeruginosa in 1.0 mL to a 1.8 cm
2
 surface area, the NO-
releasing films achieved close to complete killing after 12 h of exposure, corresponding to a 
NO payload of ~40 nmol cm
-2
. Recent work by Cai et al. examined the antibacterial and anti-
adhesive properties of a poly(lactic-co-glycolic acid) (PLGA) coating doped with the small 
molecule NO donor DBHD/NO.
91
 A composition of 20% DBHD/NO was capable of 
releasing NO for 15 d with NO fluxes from 0.6–3 pmol cm-2 s-1 at 7 d. The materials were 
exposed to S. aureus or E. coli for 7 d to allow adhesion and growth of a biofilm onto the 
surface. Confocal microscopy revealed that NO-releasing materials reduced adhesion of both 
strains while also causing cell death of those that did adhere. The NO-releasing materials 
were capable of reducing biomass of S. aureus and E. coli adhered to the substrates by 3-
orders of magnitude. 
 The in vitro evidence for the action of NO as an antimicrobial agent and in preventing 
bacterial colonization has led to in vivo investigations. Nablo et al. investigated the anti-
infective properties of NO-releasing xerogels when implanted into rats and exposed to 10 µL 
of 10
8
 CFU/mL of S. aureus.
92
 After 8 d, NO release from the implants caused an 86% 
decrease in the incidence of infection.
92
 Continuing on this research, external titanium 
fixation screws coated with NO-releasing xerogels were implanted into rat tail vertebrae.
93
 
The release of NO resulted in diminished colonization of the fixation site at 48 h and 
presentation of fewer clinical signs of infection versus control screws.
93
 However, the 
success of NO-releasing coatings to inhibit infection is concentration dependent. For 
example, Englesman et al. did not observe antibacterial properties in vivo to a C-
diazeniumdiolate implant even though decreased adhesion of several bacteria strains was 
observed in vitro.
94
 This lack of efficacy was likely due insufficient NO levels as the 
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maximum NO flux reported was ~1 pmol cm
-2
 s
-1
. Studies reported by Holt et al.
93
 and Nablo 
et al.
92
 proved successful inhibition of infection can be achieved with maximum NO fluxes of 
20 and 295 pmol cm
-2
 s
-1
, respectively. 
 While the works presented have exemplified NO as an active-releasing molecule to 
reduce adhesion in vitro and subsequently infection in vivo, the amounts necessary are poorly 
understood. The use of various materials, bacterial strains, and experimental conditions 
prevents comparisons between the studies and convolutes the data. Additionally, only a few 
studies have examined the viability of bacteria that adhere to NO-releasing surfaces. 
1.8. Summary of dissertation research 
 My dissertation research has focused on the evaluation of the effects of surface-
derived nitric oxide release on the processes involved with the implantation of materials (i.e., 
mitigation of the FBR and inhibition of bacterial adhesion and viability) and the implications 
of such effects, specifically related to implantable glucose sensors. My specific aims 
included: 
 1) Quantifying the effect of nitric oxide delivery from microdialysis probes in rat 
subcutaneous tissue on the in vivo resistances to mass transfer of glucose. 
 2) Evaluating the influence of both nitric oxide release kinetics and payloads on the 
acute and chronic foreign body response in a porcine subcutaneous model as quantified 
through collagen encapsulation and the inflammatory response. 
 3) Determining the necessary nitric oxide surface fluxes and payloads to reduce 
bacterial adhesion and to induce cell death of adhered bacteria of a range of bacterial strains. 
 The goal of this introduction chapter was to provide the current statuses of using 
microdialysis to evaluate the FBR, the effects of NO on the FBR, and the antibacterial 
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properties of NO-releasing materials. In Chapter 2, the quantification of in vivo resistances to 
mass transfer of glucose to NO-releasing microdialysis probes to evaluate the FBR over time 
will be discussed. Chapter 3 details the NO flux-dependent FBR in a porcine model through 
the evaluation of tissue histology. In Chapter 4, the NO flux- and NO payload-dependent 
effects on bacterial adhesion and viability, respectively, are examined. Finally, Chapter 5 
summarizes the research and provides future directions needed to expand on the work 
completed. 
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Chapter 2: 
Increased In Vivo Glucose Recovery via Nitric Oxide Release 
2.1. Introduction 
 The development of implantable glucose sensors that function for extended durations 
(>1 week) remains elusive primarily due to the foreign body reaction (FBR).
1, 2
 It is now 
well-known that the FBR is initiated upon protein adsorption to the implant and culminates 
with the formation of a fibrous capsule that sequesters the implant from normal tissue.
3-6
 The 
acute inflammatory response also has a significant effect on the long-term FBR and sensor 
function.
7
 The unfortunate isolation of implanted sensors via the FBR results in decreased 
analyte diffusion and analytical performance.
4, 8, 9
 Achieving extended sensor lifetimes 
requires strategies for mitigating the FBR and improving tissue integration. Prior examples of 
such strategies include the use of more hydrophilic interfaces, porous coatings, and surfaces 
that release pro-angiogenic factors and collagen inhibitory agents.
10-12
 Although some 
improvements in mitigating the FBR have been reported, none have fully resolved the 
problems that reduce the sensor lifetime in vivo. 
 Nitric oxide (NO) is an endogenously produced molecule that acts as a signaling 
mediator for cytokine production and has been used to reduce bacterial and platelet 
adhesion.
13-17
 In vivo, active release of NO from a surface has been shown to reduce bacterial 
adhesion/infection and improve implant-tissue integration by reducing inflammatory cell 
infiltration and collagen encapsulation.
18-21
 In these studies, release of NO in the first days of 
implantation significantly changed the short-term and long-term inflammatory response.
18
 As 
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such, NO release has the potential to address the difficulties with the FBR associated with 
subcutaneous sensor platforms and improve sensor function. 
 The positive effects of NO release on the FBR have not been assessed with respect to 
analyte diffusion through the developing capsule. Our hypothesis is that a thinner capsule 
may result in enhanced glucose diffusion thus improving one facet of sensor performance. 
Microdialysis allows for direct quantification of glucose diffusion through a membrane 
during the FBR. Probes are calibrated by evaluating the extraction efficiency (EE, eq 2.1.) of 
a given analyte.
22, 23
 The EE is calculated using the concentration of analyte in the perfusate, 
dialysate, and external solution represented by Cp, Cd, and Ce, respectively. The resistances to 
mass transfer through the membrane (Rm) and dialysate (Rd) are intrinsic to the individual 
probe and can be accounted for by in vitro calibration.
22
 The external resistances to mass 
transfer of biofouling (Rbf), encapsulation (Rec), and tissue trauma layers (Rtr) are dependent 
on the host response to the probe once implanted and may change with time.
23-26
 Glucose 
consumption may also be increased in wounded tissue and is thus included in the tissue 
trauma term.
27
 
 As with subcutaneous sensors, microdialysis probes suffer from diminished analyte 
diffusion with longer implantation time.
11, 26, 28
 Stenken et al. previously examined the effect 
of the FBR on analyte diffusion through a microdialysis membrane using magnetic 
resonance.
29
 Others have evaluated membrane composition and the active release of vascular 
endothelial growth factor (VEGF) or dexamethasone to alter tissue responses.
11, 26
 Neither 
altering membrane composition nor VEGF or dexamethasone release were found to 
adequately circumvent the effects that the FBR has on analyte diffusion. Herein, we evaluate 
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Equation 2.1. The mathematical definition of extraction efficiency (EE). The EE of a given 
substance is defined as the relationship of the concentrations of the molecule in the dialysate 
(Cd), perfusate (Cp), and external medium (Ce). The EE can also be related to the flow rate 
(Qd) and the resistances to mass transfer in the membrane (Rm), dialysate (Rd), biofouling 
layer (Rbf), collagen encapsulation (Rec), and tissue trauma (Rtr). 
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the influence of NO release on glucose recovery using microdialysis probes implanted 
subcutaneously in a rodent model. 
2.2. Materials and methods 
 Nitrogen, argon and nitric oxide were purchased from AirGas National Welders 
(Raleigh, NC). Glucose, glucose oxidase (type VII-S from Aspergillus niger; 168800 units/g) 
and horseradish peroxidase (type I, 118 units/mg) were purchased from Sigma (St. Louis, 
MO). CMA/20 microdialysis probes with a 10 mm polyarylethersulfone (PAES) membrane 
and 20-kDa molecular weight cutoff were purchased from CMA Microdialysis Inc (North 
Chelmsford, MA). Bioanalytical Systems (West Lafayette, IN) Baby Bee syringe pumps with 
3-syringe brackets, 1 mL Bee Stinger syringes, FEP tubing, PEEK tubing and microdialysis 
connectors were used to perfuse microdialysis probes. O-dianisidine dihydrochloride was 
obtained from Alfa Aesar (Ward Hill, MA). All other reagents used were reagent grade and 
used as received. Phosphate buffered saline (PBS; 10 mM, pH 7.4) was prepared in-house.  
PBS saturated with NO (PBS-NO; 1.9 mM NO) was prepared at room temperature by 
purging approximately 20 mL of PBS with argon gas for 20 min to remove oxygen, followed 
by nitric oxide gas for 20 min. The solution was stored at 4 °C and used up to 48 h after 
saturation. 
 2.2.1. Measurement of NO release. Real-time NO release was collected using a 
Sievers 280 Chemiluminescent NO Analyzer (Boulder, CO). The instrument was calibrated 
with an atmospheric sample that had been passed through an NO zero filter and a 25.6 ppm 
NO gas standard (balance N2). Nitric oxide release from the microdialysis probe was 
measured by immersing the probe in deoxygenated PBS at 37 °C. Solutions of PBS-NO were 
then perfused through the probe at rates of 0.5, 0.8, 1.0, 1.5, and 2.0 µL/min with NO carried 
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from the buffer to the NO Analyzer by a stream of N2 bubbled into the solution at a flow rate 
of 80 mL/min. 
 2.2.2. In vitro glucose recovery. To determine the optimal flow rate for in vivo 
studies, microdialysis probes were calibrated in well-stirred solutions of 5.5 M glucose in 
PBS at flow rates of 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, and 4.0 µL/min. Three separate dialysates 
were collected at each flow rate from each of three probes and stored at –20 °C until analysis. 
 2.2.3. Implantation and in vivo perfusion of probes. Prior to implantation, 
microdialysis probes were sterilized with ethylene oxide (gas treatment), outgassed for 7 
days to facilitate ethylene oxide desorption, and subsequently hydrated in sterile PBS for 24 
h. Probes were then calibrated in a well-stirred solution of sterile 5.5 mM glucose in PBS at a 
 low  a   o  2.0 μL/ in wi h PBS o  PBS−NO as  h  perfusate. Three separate dialysates 
w     oll        o   a h   o   an  s o    a  −20 °  un il analysis.  
 The animal protocol used in this study was approved by an IACUC committee at 
Duke University. Microdialysis   o  s w    i  lan    in o a ul   al   D  a s   50−200 g  
purchased from Charles River Laboratories (Raleigh, NC). Rats were anesthetized with 
2−4% iso lu an   v/v in O2). Two probes (one control and one NO-releasing) were then 
implanted subcutaneously in  0  a s. P o  s w     la     ila   ally 5−7     au al  o  h  
scapulae, approximately 2 cm lateral to the spine, in the dorsal subcutis with the probe tips 
oriented caudally and the inflow and outflow percutaneous catheters at the base of the neck.
 Polyether ether ketone (PEEK) or fluorinated ethylene propylene (FEP) tubing was 
used with the control probes. PEEK tubing was connected to the inlet of the NO-releasing 
probes because of its low permeability to NO. Rats were fitted into infusion harnesses with a 
spring offset attached to a dual-channel stainless steel swivel on a counter-balanced swivel 
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mount (Instech Laboratories, Plymouth Meeting, PA) to allow free movement while 
continuously perfusing probes. Immediately following implantation and for each subsequent 
 ay,   o  s w        us   a  2.0 μL/ in  o  8 h wi h   s   NO  o   on  ol     usa  . Du ing 
the last 15 min of the perfusion period, one dialysate sample was collected every 5 min and 
s o    a  −20 ° . I    ia  ly  ollowing sa  l   oll   ion, a  lood sample was taken via the 
rat tail vein to allow for blood glucose measurement using a OneTouch Ultra glucose test 
strip with a OneTouch Ultra Glucometer (LifeScan, Milpitas, CA).  
 2.2.4. Explantation and fixation of capsules. After 14 d, or after both probes failed, 
rats were anesthetized with 2-4% isoflurane (v/v in O2) to allow explantation of the probes 
with the surrounding tissue capsule intact.  Microdialysis probes were removed from the 
capsule if still functional and placed in PBS. The capsules were placed in 10% buffered 
formalin (v/v) for 24 h and then transferred to 70% ethanol for 24 h prior to their embedment 
into paraffin. Sections o   h   a a  in           a sul  w    s ain   wi h Masson’s 
trichrome or hematoxylin and eosin (H&E) for analysis.  Images of the trichrome and H&E 
stained samples were collected using 4x, 10x and 20x objectives on a Nikon Eclipse TE2000-
U with a Nikon Digital Sight DS-2Mv Digital Camera (Nikon Inc., Melville, New York).  
 2.2.5. Glucose detection. All glucose samples were measured using a colorimetric 
glucose assay in a 96-well microtiter plate format. Phosphate buffer (58.5 µL, pH 7.0) was 
added to each microtiter plate followed by addition of either dialysate (3 µL) or varying 
volumes of a standard glucose solution (1–3 µL) for a calibration curve. In the dark, a 
glucose assay mix (58.5 µL, pH 7.0) containing glucose oxidase (17.2 U/mL), horseradish 
peroxidase (3.6 U/mL) and o-dianisidine (0.43 mM) was added to each well and incubated at 
37 °C for 1 h. After incubation, 12 N sulfuric acid (80 µL) was added to end the reaction and 
39 
 
intensify the color. The absorbance of each well was measured using a Labsystems Multiskan 
RC microplate reader (Helsinki, Finland) equipped with a 540 nm filter.  
 2.2.6. Histological analysis. Histological analysis was performed on tissue adjacent to 
  o  s  un  ional ≥ 3   o  i  lan a ion. Capsule thickness was measured from trichrome-
stained tissue sample. The foreign body capsule was defined as the region of inflammatory 
cells at the probe surface and the dense collagen oriented parallel to the probe membrane. 
Two cross-sectional slides per capsule were imaged with seven measurements of the capsule 
thickness per image and averaged. Collagen density was calculated in four 400 x 100 µm
2
 
fields from each of two slides per probe using a previously developed MATLAB (The 
MathWorks, Natick, MA) program that determines the percent collagen.
10, 30
 The 
inflammatory response as determined by cell density was calculated by counting the nuclei 
between the dense collagen and probe surface in four 50 x 100 µm
2
 fields from each of two 
slides per probe using a MATLAB program.
30, 31
 
2.3. Results and discussion 
 We and others have demonstrated the promising anti-infection efficacy of and wound 
healing properties promoted by materials that spontaneously release NO.
18, 20, 21
 To date, the 
long-term benefits of NO on in vivo sensor or probe response have not been determined 
despite reduced capsule formation. Microdialysis studies allow for direct quantification of 
analyte diffusion to the implant surface as a function of implant time, a critical parameter for 
developing biocompatible in vivo sensors. In contrast to standard tissue histology, daily 
monitoring is feasible as the tissue is not disrupted for analysis, thus requiring fewer animals 
for a complete study. To evaluate the effect of NO release during the early stages of the 
wound healing process, an appropriate method for delivering NO was determined.  
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 An initial approach for achieving controlled NO release from a microdialysis probe 
focused on perfusing small molecule NO donors. First attempts to realize successful and 
consistent NO release was through utilization of the N-diazeniumdiolated form of the amino 
acid L-proline, PROLI/NO. This small molecule NO donor has a very short half life in 
physiological media (~1 min). Therefore, to deliver PROLI/NO in vivo, the NO donor was 
dissolved into a basic solution of 0.01 M NaOH, which preserved the majority of NO release 
capabilities (~90% of NO payload still available after 1 h). In vivo tests in rat subcutaneous 
tissue utilized 1 h perfusion periods over 7 d. While the NO release from PROLI/NO did 
appear to improve the glucose diffusion to the probes (n = 2), the use of 0.01 M NaOH 
solutions were found to decrease glucose diffusion compared to PBS. Therefore benefits 
gained by NO release would be, at least in part, masked by the use of the basic solutions.  
 Other small molecules were tested while only using physiological solutions, but the 
high instability of small molecule NO donors led to the formation of bubbles in the syringe, 
resulting in inconsistent flow rates, a major detriment in microdialysis studies. Therefore 
polymeric systems were implemented. Silica-based nanoparticles were explored due to their 
extended NO release, but resulted in significantly large probe failure rates. The failures were 
attributed to blocking of the probe and/or tubing by particles. A smaller polymer system was 
implemented instead to avoid this clogging issue. A N-diazeniumdiolated polyethyleneimine 
compound was synthesized as previously described.
32
 Due to the large amine content on the 
polymers, the compounds were capable of inducing pH changes in 10 mM PBS. To 
counteract this problem, a dual-syringe setup was utilized, with one syringe containing the 
PEI-NO in PBS and the other containing a low pH PBS. When the two streams combined, 
the pH dropped to ~7.4 resulting in continuous NO release from a polymer system in a 
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physiological solution. When implemented in vivo, the PEI-NO system actually resulted in 
decreases in glucose EE. This was hypothesized to be a result of incomplete mixing of the 
two streams prior to reaching the membrane and/or a increased salt content from the 
acid/base reaction. Specifically, a large salt content would induce diffusion of water into the 
probe, resulting in diminished glucose recovery. 
 As an alternative to perfusing NO donors through the microdialysis probe, a coating 
could be directly applied to the exterior of the probe. Norton et al. previously coated 
hydrogels onto microdialysis probes with only modest decreases in EE. Unfortunately, 
coating of NO-releasing polyurethane directly onto the membrane significantly diminished 
glucose recovery (EE < 30%), preventing usefulness in vivo.  We thus determined that using 
saturated NO solutions provided steady, controlled NO release without compromising the 
probe prior to implantation. 
 2.3.1. In vitro glucose extraction efficiency. To determine EE%, EE (from equation 
2.1) was multiplied by 100. An optimal microdialysis flow rate would provide a sufficiently 
large EE of glucose (0.7) to more easily detect differences in vivo. Flow rates from 0.5 to 2.0 
µL/min provided EEs of glucose from 0.7 to 0.95 while flow rates from 2.5 to 4.0 µL/min 
could only recover 0.35 to 0.55 of glucose in vitro (Figure 2.1). Th    o  , only  low  a   ≤2 
µL/min were investigated in NO studies.  
 2.3.2. Nitric oxide release from microdialysis probes. Flow rates of 0.5, 0.8, 1.0, 1.5, 
and 2.0 µL/min were investigated for their steady-state NO release when perfused with PBS-
NO solutions (Figure 2.2). As expected, the fastest flow rate (2.0 µL/min) provided the 
greatest NO flux. However, the measured NO flux was significantly less than expected from  
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Figure 2.1. Flow rate-dependent recovery of glucose in vitro to PAES microdilaysis probes. 
Data are mean ± standard deviation. 
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5
30
40
50
60
70
80
90
100
G
lu
c
o
s
e
 r
e
c
o
v
e
ry
 (
E
E
%
)
Flow rate (µL min
-1
)
43 
 
 
Figure 2.2. Flow rate-dependent NO flux from microdialysis probes. The relationship is not 
linear due to incomplete diffusion through the probe membrane and leakage through 
polyurethane microdialysis tubing. Data are mean ± standard deviation. 
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the saturated NO solution (theoretical flux = 420 pmol cm
-2
 s
-1
). Furthermore, the 
relationship of NO flux and flow rate was not linear as might be expected. For example, 
reducing the flow rate from 2.0 to 1.0 does not lead to a 50% decrease in NO flux, but instead 
resulted in a ~75% decrease in flux. While a portion of the decreased NO flux may be 
attributed to incomplete diffusion of the NO through the probe membrane, in vitro 
experiments replacing the polyurethane probe tubing with a gas impermeable PEEK tubing 
confirmed that NO diffused out of the tubing. To reduce NO loss, we attempted to replace the 
inlet tubing with gas-impermeable PEEK tubing. Unfortunately, the stiffness of the PEEK 
tubing led to a greater rate of probe failure due to undesirable mechanical stress.  Although 
the polyurethane tubing resulted in lower (~60%) NO flux, its use was necessary for enabling 
a robust set up, with levels of NO similar to previous NO-releasing xerogel materials that 
reduced the capsule formation in vivo. 
 The perfusion of PBS-NO solution through the microdialysis probe at 2.0 µL/min 
provided a constant NO flux during the perfusion period (Figure 2.3.). An 8 h perfusion 
window allowed time for the probes to be disconnected, reducing mechanical stress on the 
percutaneous implants (mechanical stress has been shown to affect wound healing in vivo).
10
  
In PBS, we measure an average NO flux of 162 ± 18 pmol cm
-2
 s
-1
, corresponding to a total 
release of 4.6 ± 0.5 µmol cm
-2
 per day over 14 d of implantation.  By releasing NO from the 
perfusate, we were able to compare the control and NO-releasing probes directly as the 
membrane material contacting the surrounding tissue remained identical.  While constant 
noise in the NO flux originating from the syringe pump noise was noted, the observed signal 
was always !3σ g  a    in agni u    Figu   2.3). 
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Figure 2.3. Representative daily NO release from a microdialysis probe over 8 h while 
flowing PBS-NO at 2.0 µL/min. 
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 2.3.3. In vivo glucose recovery. Either the glucose concentration in the external 
solution (bench studies) or the blood glucose concentration (in vivo) were used with the 
dialysate concentrations to calculate the EE using Equation 2.1 and multiplied by 100 to 
obtain EE%. Blood glucose levels were used to estimate the glucose concentration in 
subcutaneous tissue (Ce).
33
 The EE% for glucose of probes in well-stirred in vitro solutions 
using PBS an  PBS−NO was 70 ± 5 an  7  ± 5%,   s    iv ly. Th  o s  v    i     n   was 
not statistically significant and allowed for direct comparison between the control and 
experimental microdialysis probes in vivo. While the in vivo microdialysis flow rate 
employed (2.0 μL/ in   ay    l    lo al glu os  more rapidly than an implanted 
electrochemical sensor,
34
 the steady-state equilibrium established in vivo at such a flow rate 
was necessary to quantify the wound healing response. As shown in Figure 2.4, the EE% of 
NO-releasing probes remained constant over the 2 week implantation while control probes 
suffered from diminished analyte diffusion after 7 days of perfusion. As much prior work has 
noted that fibrous encapsulation diminishes diffusion of small analytes to implant surfaces, 
our results may indicate a reduced capsule thickness and ultimately improve sensor 
performance.
35
 Indeed, others have indicated that the lag in sensor response time originates
from greater resistance to mass transfer.
36
 Equally problematic, lowered analyte diffusion 
through a highly resistive fibrous capsule may interfere with glucose and oxygen levels at the 
s nso − issu  in    a  ,  h    y n ga iv ly a     ing s nso      o  an  .37 On the basis of 
the EE%, we predict that NO-releasing glucose sensor membranes would facilitate enhanced 
glucose diffusion over long implantation periods compared to controls and improve sensor 
performance. Such studies are currently underway in our laboratory. 
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Figure 2.4. Glucose recovery at various times of implantation for the NO-releasing (filled, 
red) and control (empty, black) microdialysis probes.  Data are mean ± standard error of the 
mean. Significant differences (*) are p<0.05. 
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 2.3.4. Histological analysis. Wang et al. previously reported the encapsulation of their 
microdialysis probes in a rat model after 7 days.
25
 We thus hypothesize that the EE% 
difference between NO and the control probes is the result of decreased microdialysis probe 
encapsulation from NO release. Histological analysis of the capsules surrounding NO-
releasing and control probes is shown in Figure 2.5. As expected, the thickness of the fibrous 
 a sul  su  oun ing  h  Masson’s   i h ome-stained cross sections of control probes 
(Table 2.1) was greater than that measured for the NO-releasing probes. The cross sections 
stained with H&E (Figure 2.5) also revealed decreased inflammatory cell densities at the 
NO-releasing probe membranes relative to controls, indicative of a mitigated FBR. 
Unexpectedly, the collagen density adjacent to NO-releasing was greater than that adjacent to 
control probes. 
 The cause for increased collagen density is presently unknown. While we previously 
reported a decrease in collagen density for NO-releasing xerogel membranes, others have 
reported that NO at high concentrations increases collagen deposition in wound healing.
18, 38-
40
 Of note, the xerogel system resulted in a burst of NO initially followed by significantly 
less ( 95%) NO release for 3 days. In contrast, the NO release levels used in this study 
were equivalent to daily NO bursts for 8 h. Although improving glucose recovery and 
reducing the initial FBR, our data indicates that intermittent NO bursts at large NO flux may 
negatively impact long-term wound reconstruction. Koschwanez et al. have also reported that 
percutaneous and subcutaneous implants behave differently, possibly due to mechanical 
stresses.
10
 As well, significant migration of the percutaneously implanted probes was 
observed during our study, likely caused by animal movement and resulting stress from the  
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Table 2.1.   sul s o  his ologi al analysis   o   o h h  a o ylin an   osin an  Masson’s 
trichrome stained slides. Data are mean ± standard deviation. 
Probe type 
Cell density (nuclei / 
50 x 100 µm
2
) 
Capsule thickness (µm) Collagen density (%) 
Control (n=5) 60 ± 9* 690 ± 60
†
 62 ± 6* 
NO-releasing (n=4) 38 ± 7 600 ± 70 72 ± 4 
 
*Significantly different at p<0.05 
†
Significantly different at p<0.10 
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Figure 2.5.      s n a iv  his ology sli  s o    oss s   ions s ain   wi h Masson’s   i h o   
(A and C) or hematoxylin and eosin (B and D) of NO-releasing (A and B) and control (C and 
D) probes explanted at 14 d.  Arrows in the hematoxylin and eosin stained pictures indicate 
 h    o       an .  A  ows in  h  Masson’s   i h o   s ain    i  u  s in i a    h  i  lant 
site, surrounded by dark stained inflammatory cells and the collagen capsule.  An increased 
capsule size and inflammatory response at the membrane surface are observed at control 
probes. 
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microdialysis tubing. Such stress would augment the FBR to the implanted material. Future 
studies should examine the effect of NO as a function of implant type (i.e., subcutaneous or 
percutaneous). Furthermore, NO is a potent vasodilator,
38
 and the effect of blood flow 
changes on glucose recovery using microdialysis probes is controversial.
39-41
 However, the 
glucose recovery in our model was not affected in the acute phase (<7 days) as a function of 
NO release (Figure 2.4.), indicating no effects due to NO-induced vasodilation. While 
microdialysis allowed for daily NO release and subsequent analysis of the FBR, probe failure 
remained a limitation. For example, total microdialysis probe failure rates were 30 and 65% 
over 8 and 14 days, respectively (Fig. 2.6.). With the use of these methods, studies lasting 
≥ 4  ays woul  lik ly su     si ila ly high  ailu    a  s,   ga  l ss of NO release. 
2.4. Conclusions 
 We demonstrated the benefits of in vivo NO release using microdialysis with respect 
to glucose recovery and the FBR. The observed difference in EE% obtained from glucose 
recovery data suggested improved tissue integration of the microdialysis probe. Histological 
analysis indicated that the release of NO reduced both the capsule thickness and 
inflammatory cell density at the surface. While the kinetics and total release of NO employed 
are not yet achievable through conventional NO storage/release chemistries (e.g., NO 
donors), our results support the conclusion that NO release is a viable strategy for mitigating 
the FBR and improving analyte diffusion to a sensor. Future work may determine the optimal 
NO release flux and durations and the concomitant effects of NO on long-term tissue 
viability. With the glucose diffusion to a subcutaneous implanted sensor maintained, both the 
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Figure 2.6. In vivo failure rate of microdialysis probes. All probes remained functional for 2 
d post-implant, but began to fail thereafter. Over the time course of the study (i.e. 14 d), only 
35% of probes were still functional. 
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sensitivity and response time may be enhanced circumventing previous FBR-mediated 
limitations. Studies evaluating the effects of NO release on the analytical performance of in 
vivo glucose sensors are currently underway. 
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Chapter 3: 
The Effect of Nitric Oxide Surface Flux on the Foreign Body Response  
to Subcutaneous Implants 
3.1. Introduction 
 The foreign body response (FBR) is a major impediment toward the development and 
long-term functionality of most implanted biomedical devices. Implantation disrupts the 
native tissue, initiating the FBR with the adhesion of proteins and other biomolecules to the 
device surface.
1, 2
 This process continues with the infiltration of inflammatory cells that 
attempt to phagocytose the foreign object.
1, 2
 Within a few weeks, the cells create a relatively 
avascular collagen-rich encapsulation, effectively sequestering the implant from the 
surrounding tissue.
3
 Macrophages undergo cell fusion to form multi-nucleated foreign body 
giant cells (FBGCs) that remain at the implant surface and enhance its degradation, often 
leading to device failure or performance mitigation.
4, 5
 In the case of implanted glucose 
sensors, this isolation blocks the diffusion of glucose from surrounding tissue, inhibiting 
accurate measurements. 
 Efforts to improve the fate of subcutaneous implants have largely focused on 
developing materials with chemical and physical properties that mitigate the FBR and allow 
better tissue integration. The use of natural materials (e.g., collagen)
6, 7
 and synthetic 
polymers
8, 9
 to alter the tissue-sensor interface has slightly improved tissue integration of 
such devices. However, complete avoidance of the FBR has yet to be achieved and the field 
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of biomaterials has evolved to include the design of coatings that actively release FBR 
mediators.
10
 For glucose sensors, the focus has been on materials that release anti-
inflammatory (i.e., dexamethasone) and/or pro-angiogenic (i.e., vascular endothelial growth 
factor (VEGF)) mediators.
11-14
 Unfortunately, reports on the combined use of dexamethasone 
and VEGF have been controversial, possibly due to the molecules acting in an antagonistic 
manner.
13-16
 
 Other work has focused on the design of interfaces that release nitric oxide (NO) and 
endogenous signaling molecule that plays multiple roles in the immune response including an 
initiator of cytokine production,
17, 18
 collagen deposition,
19-22
 angiogenesis,
23
 and anti-
microbial activity.
24
 Hetrick et al. examined the subcutaneous in vivo response to NO-
releasing N-diazeniumdiolated xerogels coated onto rectangular silicone rubber substrates.
25
 
These coatings released ~1.35 µmol/cm
2
 of NO over 72 hours with 50% of the NO payload 
exhausted within 5 h. A >50% decrease in collagen capsule thickness was observed after 3 
weeks of implantation.
25
 Furthermore, NO release reduced the chronic inflammation at 3 and 
6 weeks while enhancing angiogenesis adjacent to the implant after only 1 week of 
implantation.
25
 As found in Chapter 2, mitigation of the FBR with NO release was found to 
improve glucose diffusion to NO-releasing microdialysis probes after 7 days of implantation 
in rat subcutaneous tissue which would effectively decrease implantable glucose sensor lag 
time.
26
 In this case, 4.6 µmol NO/cm
2
 was released each day by perfusing saturated NO 
solutions for 8 h over 14 d of implantation.
26
 Histological analysis at 14 d revealed a thinner 
collagen capsule and reduced inflammatory response for the NO-releasing probes.
26
 Gifford 
et al. prepared subcutaneous glucose sensors capable of releasing NO for 18 h by doping the 
NO donor (Z)-1-[N-methyl-N-[6-(N-butylammoniohexyl)amino]]-diazen-1-ium-1,2-diolate 
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(DBHD/N2O2) into a polymer matrix.
27
 The in vivo inflammatory response was significantly 
reduced in response to the NO-releasing materials after implantation of 24 h but not at 48 h.
27
 
The authors noted that the reduction in the inflammatory response correlated well with the 
NO release duration, supporting a need for long-term NO release.
27
 Decreased collagen 
encapsulation and inflammation with increased angiogenesis have been identified previously 
as key factors that enhance glucose sensor function.
28
 Taken together, these reports support 
the promise of improved tissue integration and subcutaneous sensor functionality using 
materials that release NO. 
 While the positive effects of NO are well known, the optimal rate and amounts of NO 
release are unclear. Previously, Koh et al. reported the ability to dope NO-releasing 
nanoparticles of various compositions into polyurethane (PU) matrices and control the NO 
release kinetics based on the properties of the PU and/or NO-releasing scaffold.
29
 The NO-
releasing properties from these materials suggest that they are idea for systematically 
studying the effect of NO on the FBR from chemically identical interfaces. To better mimic 
the human FBR and wound healing, this study is carried out in a porcine subcutaneous 
implant model.
30
 
3.2. Materials and methods 
 Tetramethoxysilane (TMOS) and L-proline were purchased from Sigma Aldrich (St. 
Louis, MO). 3-Mercaptopropyltrimethoxysilane (MPTMS), N-(2-aminoethyl)-3-
aminopropyltrimethoxysilane (AEAP3), and tetraethoxysilane (TEOS) were purchased from 
Gelest (Tullytown, PA). Diethylenetriamine pentaacetic acid (DTPA) was purchased from 
Fluka (Buchs, Switzerland). Ethanol (EtOH), methanol (MeOH), tetrahydrofuran (THF), and 
ammonia solution (NH4OH, 30 wt % in water) were purchased from Fisher Scientific (Fair 
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Lawn, NJ). Stainless steel wire (316L, 381 µm diameter) was purchased from McMaster-
Carr (Atlanta, GA). Tecoplast TP-470-000 (TP-470), Tecophillic HP-93A-100 (HP 93A) and 
Tecoflex SG-80A (TPU) were gifts from Thermedics (Woburn, MA). Hydrothane AL 25-
80A (HPU) was a gift from AdvanSource Biomaterials Corporation (Wilmington, MA). 
Nitric oxide was purchased from Praxair (Danbury, CT). Nitric oxide calibration gas (26.39 
ppm; balance nitrogen), nitrogen, and argon were purchased from National Welders (Raleigh, 
NC). Distilled water was purified to 18.2 MΩ/cm with a Millipore Milli-Q Gradient A-10 
water purification system (Bedford, MA). All other reagents were reagent grade and used as 
received. 
 3.2.1. Preparation of NO-releasing scaffolds. 1-[2-(carboxylato)pyrrolidin-1-
yl]diazen-1-ium-1,2-diolate (PROLI/NO) was prepared by converting the secondary amine in 
L-proline to an N-diazeniumdiolate following a previously described procedure.
31
 Nitric 
oxide-releasing silica particles were synthesized based on the sol–gel process via the co-
condensation of AEAP3 (70 mol% balance TMOS) or MPTMS (75 mol% balance TEOS).
32, 
33
 Subsequent N-diazeniumdiolation of the amine- containing particles was performed under 
high pressure of NO for 3 d in the presence of sodium methoxide in methanol at room 
temperature.
32
 Nitrosation of the thiol-containing nanoparticles was carried out by reaction 
with acidiﬁed nitrite in the dark at 0 °C.33 The details of the NO-releasing characteristics for 
each system are provided in Table 3.1. 
3.2.2. Preparation of polyurethane-coated wire substrates. Stainless steel wires were 
cut to ~5 cm and cleaned by sonicating sequentially in EtOH, water, and EtOH again for 30 
min each and sterilized by autoclaving. To create the NO-releasing coating, the NO-releasing 
vehicle (i.e., PROLI/NO, AEAP3 nanoparticles or MPTMS nanoparticles) was dispersed into  
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Table 3.1. Nitric oxide release properties of silica nanoparticles at pH 7.4 and 37 °C. Data 
are mean ± standard deviation. 
Nanoparticle system Max flux (pmol mg
-1
) tmax (min) t1/2 (min) total NO (µmol mg
-1
) 
AEAP3 145 ± 28 1.13 ± 0.27 185 ± 35 2.05 ± 0.06 
MPTMS 241 ± 35 1.87 ± 0.31 213 ± 20 2.95 ± 0.25 
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cold EtOH (2.5 mL) at concentrations of 36 or 72 mg/mL. This solution was then mixed with 
an equal volume of 50:50 wt% HPU/TPU (160 mg/mL total PU) dissolved in THF (2.5 mL) 
for a resulting concentration of 18 or 36 mg/mL scaffold and 80 mg/mL PU in 50:50 v/v 
EtOH/THF. In a sterile laminar flow hood, wires were then dip-coated four times in the 
scaffold-containing PU solution with brief ambient drying between dips. A polyurethane 
topcoat (TP-470, TPU, HPU/TPU, HPU or HP 93A; 40 mg/mL dissolved in THF) was then 
applied and allowed to dry. The PU-coated wire was then cut to 3 cm, and the freshly cut end 
was coated with the same PU topcoat. The PU-modified wires were placed into individual, 
sterile, microcentrifuge tubes and kept vacuum sealed in the dark at -20 °C until use. Control 
(non-NO-releasing) wires were made using the same protocol but with no scaffold in the PU 
solutions. 
 3.2.3. Characterization of polyurethane-coated wires. Scanning electron microscopy 
was used to evaluate the macroscopic surface roughness of the coated wires using a Quanta 200 (FEI, 
Hillsboro, OR) in high vacuum mode before and after the topcoating process. Release of NO was 
measured continuously using a Sievers 280i Chemiluminescence Nitric Oxide Analyzer (NOA) 
(Boulder, CO).
34
 Calibration of the NOA was performed with both air passed through a 
Sievers NO zero filter and 26.39 ppm NO gas (balance N2). For analysis, NO-releasing wire 
substrates were immersed in 25 mL of deoxygenated phosphate buffered saline (PBS; 10 
mM, pH 7.4). Released NO was carried to the analyzer in a nitrogen stream (200 mL min
−1
). 
Temperature control was maintained using a water bath at 37 °C. Nitric oxide release from 
nitrosothiol nanoparticle-doped coatings were studied by shielding the sample flask from 
light and using PBS with 500 μM DTPA to chelate trace copper. The thickness of the wire 
coatings was estimated by optical microscopy. 
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 3.2.4. Silicon elemental analysis. To characterize particle stability (via leaching) in 
the various polyurethane polymers, substrates were incubated at 37 °C in PBS (1 mL) for 1, 3 
and 6 weeks. Samples were then further prepared for Si elemental analysis by adding aqua 
regia (2.5 mL), hydrofluoric acid (1 mL), and 40% triethanolamine (3.575 mL) to dissolve 
the particles, and then diluted to 50 mL with water. To determine the mass of silica 
nanoparticles contained in the PU films, the coatings were dissolved in piranha solution (1 
mL), exposed to hydrofluoric acid (1 mL) and 40% triethanolamine (3.575 mL), then diluted 
to 50 mL with water. (CAUTION: hydrofluoric acid and piranha are extremely corrosive and 
require special handling). The silicon concentration in the solutions was subsequently 
measured using inductively coupled plasma-optical emission spectroscopy (ICP-OES; 
Prodigy, Teledyne Leeman Labs, Hudson, NH).  
 3.2.5. Implantation and explantation of wire substrates. The animal protocol used in 
this study was reviewed and approved by the IACUC at Duke University. Coated wire 
substrates were implanted into seventeen mixed breed Yorkshire-type piglets weighing 
approximately 5–7 kg. Pigs were initially anesthetized with ketamine:xylazine (20 mg/kg and 
2 mg/kg, respectively) and maintained on 2–4% isoflurane (v/v in O2) during implantation. 
The dorsal skin was prepared by clipping of the hair and triplicate scrubbing with 
chlorhexidine and alcohol. Four 1 cm incisions were created 4 cm lateral to the dorsal 
midline and 8 cm and 18 cm caudal to the scapulae using a scalpel. Five or six wires were 
then inserted radially (“clock hour” pattern) in the 2, 4, 6, 8, 10, and 12 o’clock positions, 
extending 2 cm out from the incision. The 6 o’clock position was eliminated in two caudal 
implant sites, resulting in 22 wires implanted per pig. 
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 After 3, 7, 21 or 42 d, pigs were anesthetized and the tissue surrounding the wire 
implants was explanted and placed into 10% buffered formalin (v/v) for 24 h, then 
transferred to 70% EtOH (v/v in H2O) for at least 24 h prior to embedding into paraffin. 
Sections of the paraffin embedded tissue were stained with Masson’s trichrome or 
hematoxylin and eosin (H&E). Micrographs of the trichrome and H&E stained samples were 
collected using 4, 10, and 20X  objectives on a Nikon Eclipse TE2000-U with a Nikon 
Digital Sight DS-2Mv digital camera (Nikon Inc., Melville, NY).  
 3.2.6. Histological analysis. Histological analysis was performed on all explanted 
tissue samples. Capsule thickness was measured from Masson’s trichrome-stained tissue 
sections.  The foreign body capsule was defined as beginning at the edge of the implant and 
consisting of the region of dense collagen oriented parallel to the implant. The end of the 
capsule thickness was determined to be where collagen was no longer the primary tissue 
constituent (indicated by a decrease in the density of blue-green stain) nor oriented parallel to 
the surface. Eight capsule thickness measurements, taken radially at 45° intervals, were 
averaged for each image.  Three images of the collagen capsule were processed using a 
previously developed MATLAB (The MathWorks, Natick, MA) program that quantifies the 
percent collagen.
35, 36
 The program defines collagen from trichrome-stained images by the 
characteristic blue-green color, divides the number of collagen positive pixels by the total 
pixels in the image, and multiplies this ratio by 100 to obtain the percent collagen.  
Hematoxylin and eosin-stained tissue sections were used to measure the inflammatory 
response. The inflammatory response, as determined by cell density, was determined by 
counting all cell nuclei within 50 µm of the implant surface from three 50 x 100 µm
2
 fields 
from each slide. Cell nuclei were defined as the purple-stained, spherical features in the 
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H&E-stained tissue sections. Histology data are expressed as mean ± standard error of the 
mean and tested for significance (i.e., p < 0.05) using a non-parametric Wilcoxon rank-sum 
test. 
3.3. Results and discussion 
 3.3.1. Characterization of polyurethane coatings. Wire substrates were successfully 
coated with particle-doped polyurethanes (PUs) capable of releasing NO via dip-coating. The 
use of wire substrates was pursued to mimic the shape and size of an electrochemical glucose 
sensor. Both size and shape have been shown to affect the FBR.
37, 38
  The thickness of the PU 
coatings remained constant even with the incorporation of a range of NO-releasing scaffold 
and concentrations. For example, control PU and 36 mg/mL MPTMS nanoparticle-doped PU 
coatings were 46 ± 4 and 49 ± 4 µm, respectively. Prior to topcoating, the particle-doped 
films exhibited significantly greater surface roughness than controls as evaluated using SEM 
(Fig. 3.1.A). As previous in vivo studies have reported that surface roughness may 
significantly alter the FBR,
39, 40
 a PU topcoat was added (Fig. 3.1.B) to ensure that the tissue 
response observed in vivo was a result of NO release and not physical properties. 
 Although silica is generally considered non-toxic,
41
 leaching of nanoparticles was 
quantified to address concerns of unexpected effects in vivo. To determine the percentage of 
silica particles leached, the mass of nanoparticles within the films was measured by 
dissolving the PU coatings and quantifying via ICP-OES. Wires dipcoated in 36 mg/mL 
AEAP3 nanoparticle-doped PU and 36 mg/mL MPTMS nanoparticle-doped PU contained 
1.1 ± 0.2 mg and 1.2 ± 0.1 mg of silica nanoparticles, respectively. Over 6 weeks, AEAP3 
nanoparticles leached 4.2 ± 0.7% of the total loaded scaffold, with the majority of the 
leaching (>90%) occurring during the first 3 weeks (Fig. 3.2). The MPTMS soak
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Figure 3.1. Scanning electron microscope images of polyurethane-coated wire substrates A) 
dipcoated four times in 36 mg/mL MPTMS nanoparticles in 80 mg/mL HPU/TPU before topcoating, 
and B) after topcoating with a 40 mg/mL HPU/TPU solution. Nanoparticle-induced surface roughness 
is masked after topcoating. 
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Figure 3.2. Cumulative leaching from HPU/TPU topcoated 36 mg/mL AEAP3 nanoparticle 
system over 6 weeks as quantified by ICP-OES. More than 90% of the total leaching occurs 
over the first 3 weeks. Over the maximum length of the in vivo study (i.e., 6 weeks), 4.2% of 
the AEAP3 nanoparticles may leach from the polyurethane. 
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solutions had no detectable leaching, likely due to the larger particle size of the MPTMS 
(~750-900 nm) compared to the AEAP3 (~110-150 nm) nanoparticles. 
 3.3.2. Nitric oxide release from polyurethane films.   To evaluate the effect of NO 
release kinetics on the FBR, several NO-releasing scaffolds were employed including 
PROLI/NO, AEAP3, and MPTMS. The low molecular weight (LMW) N-diazeniumdiolate 
PROLI/NO provided the fastest NO release with >90% of NO storage liberated after 6 min. 
Longer durations of NO release from N-diazeniumdiolate donors was achieved using a 
hybrid silica nanoparticle scaffold containing AEAP3 with a NO release half-life of 185 min. 
By varying the water uptake by selection of the PU topcoat, NO release kinetics were further 
tuned for N-diazeniumdiolate systems whereby NO donor composition is proton initiated.
42, 
43
 As shown in Table 3.2, the four PUs used in the study were chosen in part due to their 
water uptake.
29
 
 The release of NO from N-diazeniumdiolate and S-nitrosothiol NO donors follows 
pseudo first-order kinetics. Although doping the NO donors into polyurethane matrices may 
slow NO donor breakdown (and thus NO release), the materials still follow approximate 
first-order kinetics, with an initial maximum and exponential decay in NO flux. Due to rapid 
NO donor breakdown, LMW PROLI/NO-doped PUs released NO rapidly (~24 h) and with 
the greatest NO fluxes (1400 to 3100 pmol cm
-2
 s
-1
) depending on the polyurethane matrix 
(Table 3.3). The prominent burst of NO may impact the FBR. For example, exogenous NO 
has been shown to inhibit platelet adhesion and aggregation, and thus elevated NO may slow 
early healing.
44, 45
 Compared to the PROLI/NO-doped polymers, the NO release from 
AEAP3 nanoparticle-doped PUs (Tables 3.4 and 3.5) was significantly longer in duration (up 
to 72 h) compared to the PROLI/NO-doped polymers due to the longer half-life of the
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 Table 3.2. Water uptake of polyurethane topcoats.
29
 Data are mean ± standard deviation. 
Polyurethane Water Uptake (mg H2O/mg PU) 
Tecophillic HP-93A-100 (HP 93A) 2.6 ± 0.3 
Hydrothane AL 25-80A (HPU) 0.63 ± 0.3 
Tecoflex SG-80A (TPU) 0.20 ± 0.2 
Tecoplast TP-470-000 (TP-470) 0.04 ± 0.05 
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Table 3.3. Nitric oxide release from coatings doped at 18 mg/mL PROLI/NO as a function of 
polyurethane topcoat. Data are mean ± standard deviation. 
NO release properties 
Type of polyurethane topcoat 
HP 93A HPU HPU/TPU TPU TP-470 
[NO]max (pmol cm
-2
 s
-1
) 3100 ± 700 2900 ± 400 2600 ± 400 1500 ± 200 1400 ± 300 
tmax (min) 8.4 ± 0.8 8.4 ± 0.6 9.1 ± 0.5 18 ± 1 17 ± 3 
[NO]6 h (pmol cm
-2
 s
-1
) 5 ± 2 7 ± 2 23 ± 4 28 ± 4 27 ± 4 
[NO]12 h (pmol cm
-2
 s
-1
) 0 1.9 ± 0.2 2.5 ± 0.4 5.7 ± 0.7 7.0 ± 0.8 
[NO]24 h (pmol cm
-2
 s
-1
) 0 0 0.9 ± 0.3 1.7 ± 0.3 2.0 ± 0.3 
Total NO (µmol cm
-2
) 3.9 ± 0.4 3.8 ± 0.5 4.1 ± 0.5 4.2 ± 0.5 4.1 ± 0.4 
  
 
 
 
72 
 
Table 3.4. Nitric oxide release from coatings doped at 18 mg/mL AEAP3 nanoparticles as a 
function of polyurethane topcoat. Data are mean ± standard deviation. 
NO release properties 
Type of polyurethane topcoat 
HP 93A HPU HPU/TPU TPU TP-470 
[NO]max (pmol cm
-2
 s
-1
) 110 ± 20 100 ± 20 100 ± 20 80 ± 20 42 ± 9 
tmax (min) 9 ± 1 7 ± 1 19 ± 3 70 ± 20 80 ± 20 
[NO]6 h (pmol cm
-2
 s
-1
) 28 ± 4 50 ± 5 45 ± 5 43 ± 6 38 ± 8 
[NO]12 h (pmol cm
-2
 s
-1
) 11 ± 2 19 ± 3 21 ± 2 19 ± 1 22 ± 4 
[NO]24 h (pmol cm
-2
 s
-1
) 1.0 ± 0.3 1.9 ± 0.2 2.3 ± 0.3 5.6 ± 0.9 11 ± 2 
[NO]48 h (pmol cm
-2
 s
-1
) 0 0.98 ± 0.04 1.13 ± 0.08 1.37 ± 0.09 1.7 ± 0.2 
Total NO (µmol cm
-2
) 2.7 ± 0.3 3.0 ± 0.3 3.0 ± 0.4 2.8 ± 0.3 2.7 ± 0.3 
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Table 3.5. Nitric oxide release from coatings doped at 36 mg/mL AEAP3 nanoparticles as a 
function of polyurethane topcoat. Data are mean ± standard deviation. 
NO release properties 
Type of polyurethane topcoat 
HP 93A HPU HPU/TPU TPU TP-470 
[NO]max (pmol cm
-2
 s
-1
) 350 ± 90 320 ± 70 320 ± 70 189.2 ± 51.4 123.4 ± 36.1 
tmax (min) 7.2 ± 0.9 6.6 ± 0.8 18 ± 3 72 ± 19 96 ± 21 
[NO]6 h (pmol cm
-2
 s
-1
) 90 ± 10 93 ± 9 110 ± 10 68 ± 7 87 ± 7 
[NO]12 h (pmol cm
-2
 s
-1
) 30 ± 4 36 ± 3 39 ± 3 42 ± 4 52 ± 6 
[NO]24 h (pmol cm
-2
 s
-1
) 2.8 ± 0.7 3.6 ± 0.4 5 ± 1 10 ± 2 11 ± 1 
[NO]48 h (pmol cm
-2
 s
-1
) 1.0 ± 0.2 1.12 ± 0.06 1.4 ± 0.3 2.6 ± 0.6 2.8 ± 0.4 
[NO]72 h (pmol cm
-2
 s
-1
) 0 0.92 ± 0.04 1.2 ± 0.2 1.28 ± 0.08 1.6 ± 0.2 
Total NO (µmol cm
-2
) 6.1 ± 0.6 6.1 ± 0.5 6.0 ± 0.5 5.9 ± 0.6 5.8 ± 0.5 
 
 
 
74 
 
AEAP3 nanoparticles. As expected for each of the PROLI/NO and AEAP3 systems, the total 
NO payload for any given scaffold and concentration was the same regardless of topcoat. In 
contrast to the N-diazeniumdiolate-based scaffolds, S-nitrosothiols decompose when exposed 
to heat, light, or Cu
+
 to form 1 mol of NO per mol of thiol.
46
 Furthermore, the decomposition 
of S-nitrosothiols is not affected by water uptake and therefore only the HPU/TPU 
polyurethane topcoat was utilized for MPTMS nanoparticle-doped PUs. While the MPTMS 
nanoparticles have similar initial release kinetics as the N-diazeniumdiolate systems, the S-
nitrosothiol nanoparticles release lower levels of NO over long periods through thermal 
release mechanisms.  As expected, the MPTMS nanoparticle-doped PUs released NO for the 
longest duration, with NO still detectable at 14 d (Table 3.6). Of note, previously implanted 
NO release studies are based on materials capable of uninterrupted NO release for up to 3 
d.
25, 27
 The 36 mg/mL MPTMS nanoparticle-doped PUs produced the greatest NO payload 
(9.3 µmol cm
-2
) in this study, ~7 times more NO than previous subcutaneous NO-releasing 
xerogels.
25
 Based on the nanoparticle concentrations measured via the ICP-OES leaching 
study, the predicted total NO release for the 36 mg/mL AEAP3 and MPTMS nanoparticle-
doped PUs are 6.3 and 10.1 µmol cm
-2
, respectively. The slight loss in NO likely occurs 
during the wire dipcoating process. Moisture, light, and heat that are unavoidable under 
ambient conditions may initiate NO release from both N-diazeniumdiolate- and S-
nitrosothiol-based scaffolds. The range of NO release kinetics utilized in this study allowed 
for the investigation of the effects of NO release flux (initial burst versus sustained delivery) 
to be compared. 
 3.3.3. Collagen deposition. A characteristic event of the FBR is collagen 
encapsulation that begins to form 1–2 weeks after implantation. The capsule persists for the
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Table 3.6. Nitric oxide release from coatings doped at 18 mg/mL or 36 mg/mL MPTMS 
nanoparticles with a HPU/TPU polyurethane topcoat. Data are mean ± standard deviation. 
NO release properties 
Nanoparticle concentration doped into polyurethane 
18 mg/mL 36 mg/mL 
[NO]max (pmol cm
-2
 s
-1
) 290 ± 20 380 ± 30 
tmax (min) 9 ± 2 9 ± 2 
[NO]6 h (pmol cm
-2
 s
-1
) 32 ± 2 74 ± 7 
[NO]12 h (pmol cm
-2
 s
-1
) 14 ± 2 31 ± 3 
[NO]24 h (pmol cm
-2
 s
-1
) 6.8 ± 0.6 13 ± 1 
[NO]72 h (pmol cm
-2
 s
-1
) 2.7 ± 0.3 5.2 ± 0.4 
[NO]7 d (pmol cm
-2
 s
-1
) 1.6 ± 0.1 1.7 ± 0.1 
[NO]14 d (pmol cm
-2
 s
-1
) 1.1 ± 0.1 1.3 ± 0.1 
Total NO (µmol cm
-2
) 5.1 ± 0.4 9.3 ± 0.6 
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life of the device has low microvessel density,
3, 47
 impeding diffusion of analytes from the 
surrounding native tissue and blood capillaries.
48
 For glucose sensors, the collagen capsule 
results in reduced sensitivity and increased lag time.
49-52
 Capsule thickness and collagen 
density via Masson’s trichrome-stained histology was thus evaluated as a function of NO 
release kinetics and doses. 
 As expected, collagen capsule formation surrounding PU-coated wire substrates was 
not observed until 3 weeks following implantation. The collagen capsule thickness for all 
wire substrates after 3 and 6 weeks of implantation are provided in Fig. 3.3. At 3 weeks (Fig. 
3.3.A), PROLI/NO-doped PUs showed no significant reduction in the collagen capsule 
thickness relative to control (p < 0.05). In contrast, both the TPU and TP-470 PU topcoats 
significantly reduced collagen capsule formation for both the 18 mg/mL and 36 mg/mL 
AEAP3 nanoparticle-doped PUs versus controls. Both TPU and TP-470 are characterized by 
low water uptake and thus enabled the longest NO release for the N-diazeniumdiolate 
particle-doped PU systems. The data from the AEAP3 nanoparticle-doped PUs suggest that 
longer NO-releasing substrates with similar NO payloads are more successfully mitigate the 
FBR. Furthermore, the data suggests that the total NO payload may be less important than 
the NO release kinetics for reducing collagen encapsulation at 3 weeks. For example, the TP-
470 topcoated 18 mg/mL AEAP3 nanoparticle-doped PU has a lower total NO payload but a 
greater NO flux at 48 h than HP 93A, HPU or HPU/TPU topcoated 36 mg/mL AEAP3 
nanoparticle-doped PUs (Tables 3.4 and 3.5). These slow NO release kinetics correlate well 
with the mitigated FBR. The even longer (in duration) NO-releasing PUs (i.e., MPTMS 
nanoparticle-doped) reduced the collagen capsule at both dopant concentrations of 18 and 36 
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Figure 3.3. Collagen capsule thickness surrounding polyurethane-coated wire substrates at A) 3 and 
B) 6 weeks. Significant differences between NO-releasing and relative controls are indicated at p < 
0.05 (*).At 6 weeks, the TP-470 topcoated 18 mg/mL AEAP3 nanoparticle system was not tested due 
to low sample size (n = 2). Data are mean ± standard error of the mean. 
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mg/mL by ~64 and ~77%, respectively. Indeed, the MPTMS nanoparticle-doped PU systems 
represented the two largest decreases in collagen capsule thickness at 3 weeks. 
 At 6 weeks, the average collagen capsule thickness adjacent to all implanted materials 
was reduced compared to 3 weeks. While not anticipated, a decrease in collagen 
encapsulation surrounding subcutaneous materials has been observed over time for non-NO-
releasing materials 
53
. As was also observed at 3 weeks, PROLI/NO-doped PUs did not 
appreciably reduce the collagen capsule thickness (Fig. 3.2.B). Of the 18 mg/mL AEAP3 
nanoparticle-doped PUs, only the HPU/TPU topcoated system displayed a significant 
reduction in capsule thickness (~59% reduction vs. control). It is currently unknown why this 
composition would best mitigate the FBR. The other 18 mg/mL AEAP3 nanoparticle-doped 
PU systems with slightly longer or shorter NO durations proved inadequate in altering the 
resulting capsule thickness. Although speculative at this stage, we believe that the NO release 
from the HPU/TPU topcoat provided both a sufficiently high maximum and NO release 
duration. Other PU topcoats resulted in either insufficient maximum NO flux or duration 
negatively impacting the FBR mitigation. Clearly other relevant parameters are likely since 
materials with a greater maximum flux and similar NO flux at 48 h (e.g., HPU topcoated 36 
mg/mL AEAP3 nanoparticle-doped PUs) did not result in similar reductions in capsule 
thickness. 
 In contrast to the 18 mg/mL AEAP3 nanoparticle-doped PUs, the three longest NO-
releasing PU topcoats (i.e., HPU/TPU, TPU, and TP-470) applied to the 36 mg/mL AEAP3 
nanoparticle-doped PU systems were capable of significant reductions in the capsule 
thickness at 6 weeks. The higher incidence of significant capsule thickness reductions with 
the 36 versus the 18 mg/mL AEAP3 nanoparticle system indicates a possible advantage to 
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materials releasing a greater NO payload. The NO release originating from low water uptake 
PU topcoats (i.e., HPU/TPU, TPU, and TP-470) provided the longest NO release duration for 
the 36 mg/mL AEAP3 nanoparticle system albeit with identical NO payloads to the 
statistically insignificant PU topcoats (i.e., HP 93A and HPU). The data from the 36 mg/mL 
AEAP3 nanoparticle systems further indicates that NO release kinetics of implanted 
materials greatly impact the FBR. Both concentrations of the MPTMS nanoparticle-doped 
polyurethanes significantly reduced the capsule size with the 18 and 36 mg/mL MPTMS 
nanoparticle systems achieving a ~50 and ~76% reduction in capsule thickness, respectively. 
Since the long-term NO release fluxes (i.e., 7 to 14 d) for both the 18 and 36 mg/mL 
MPTMS nanoparticle systems were similar (Table 3.6), the difference in the initial 7 d of NO 
release is attributed to the enhanced FBR mitigation. The combination of significant NO 
levels initially and sustained, low NO release over 14 d may improve tissue integration by 
altering the initial inflammatory response.
25
 The 36 mg/mL MPTMS nanoparticle-doped 
systems reduced the collagen encapsulation to the greatest level at both 3 and 6 weeks of 
implantation, indicating the advantage of a large initial NO payload and sustained NO release 
for decreasing capsule thickness.  
 The density of the collagen within the encapsulation is another factor that may affect 
the sequestering of the foreign body. A previously developed and implemented MATLAB 
program was thus used to quantify collagen density in captured micrographs of the collagen 
capsule.
54
 The program measures the number of pixels attributed to collagen when stained 
with Masson’s trichrome, divides this number by the total pixels in the image, and multiplies 
by 100 to give a collagen density index (CDI) ranging from 0 to 100, with a CDI value of 
100 indicating every pixel represents collagen. At 3 weeks, the capsules surrounding the HP 
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93A, HPU, and TPU topcoated PROLI/NO systems exhibited significantly increased CDI 
compared to controls (Fig. 3.4.A) with no other NO-releasing substrates exhibiting a 
significant change. Of note, the maximum NO flux from PROLI/NO-doped PUs was an 
order of magnitude greater (1400 to 3100 pmol cm
-2
 s
-1
) than that from any previously 
implanted NO-releasing materials. Though the NO payload (~4 µmol/cm
2
) from the 
PROLI/NO systems falls between that of the two concentrations of AEAP3 nanoparticle 
systems, neither concentration of AEAP3 nanoparticle systems exhibited an increase in CDI 
at 3 weeks. As such, the CDI enhancement is most likely the result of the large NO bolus 
from the PROLI/NO systems. The inability to significantly reduce capsule thickness while 
simultaneously causing an increase in the collagen density indicates long-term disadvantages 
of bolus NO release from implant surfaces. 
  At 6 weeks, the capsules surrounding the TP-470 topcoated 36 mg/mL AEAP3 and 
HPU/TPU topcoated 36 mg/mL MPTMS nanoparticle systems showed significantly 
increased CDI versus controls (Fig. 3.4.B). This enhancement of collagen density at 6 weeks 
may also be the result of too much NO. Previously reported microdialysis implants with high 
NO payloads (4.6 µmol cm
-2
 each day) also increased collagen density,
26
 perhaps not 
unexpected since NO has been shown to enhance collagen deposition from fibroblasts.
20-22
 
Nevertheless, the NO-releasing microdialysis probes resulted in superior glucose recovery 
compared to control probes despite an enhanced CDI.
26
 While the TP-470 topcoated 36 
mg/mL AEAP3 and the HPU/TPU topcoated 36 mg/mL MPTMS nanoparticle systems were 
characterized by increased CDI, both of these materials significantly reduced the thickness of 
the collagen encapsulation. Therefore, the materials may still be advantageous for certain 
subcutaneous device applications (e.g., glucose sensors).  
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Figure 3.4. Collagen density index (CDI) of collagen capsules surrounding polyurethane-coated 
wire substrates at A) 3 and B) 6 weeks. Significant differences between NO-releasing and relative 
controls are indicated at p < 0.05 (*). At 6 weeks, the TP-470 topcoated 18 mg/mL AEAP3 
nanoparticle system was not tested due to low sample size (n = 2). Data are mean ± standard error 
of the mean. 
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 3.3.4. Inflammatory response.The localization of inflammatory cells may contribute 
to erratic device performance (e.g., sensor) and ultimate failure.
55
 Inflammatory cells 
adjacent to the implant become activated while attempting to phagocytose the foreign body. 
This activation decreases local pH and produces superoxide and peroxide. Several studies  
have linked these factors to poor sensor performance.
55-57
 As the FBR progresses, the 
formation of foreign body giant cells (FBGCs) enhances implant degradation, also 
diminishing the sensor lifetime.
4, 5
 To quantify the inflammatory response, the number of cell 
nuclei localized within 50 µm of the implant surface was measured in hematoxylin and 
eosin-stained histology sections. For these reasons, the inflammatory response to the NO-
releasing substrates was examined histologically at both acute (3 and 7 d) and chronic (3 and 
6 week) stages. 
 During the acute phase, the NO release led to a significant reduction in the 
inflammatory response (Fig. 3.5.A and 3.5.B). The inflammatory response was most 
significantly impacted by substrates with large and long NO release (e.g., 36 mg/mL AEAP3 
and MPTMS nanoparticle systems). The PROLI/NO and 18 mg/mL AEAP3 nanoparticle 
systems, only releasing NO up to 48 h, did not decrease the inflammatory response. 
Likewise, Gifford et al. reported that the inflammatory response only seemed to be 
influenced (reduced) while NO was actively released.
27
 However, the HPU/TPU topcoated 
18 mg/mL AEAP3 nanoparticle system was also observed to decrease the inflammatory 
response, likely due to the achievement of release kinetics and duration via the HPU/TPU 
topcoat. Of the 36 mg/mL AEAP3 nanoparticle systems, the three topcoats with the slowest 
NO release kinetics (i.e., HPU/TPU, TPU, and TP-470) also significantly reduced the 
inflammatory cell density adjacent to the implant. The difference in inflammation with 
83 
 
 
Figure 3.5. Inflammatory response to polyurethane-coated wire substrates at A) 3 d and B) 1, C) 3, 
and D) 6 weeks. Significant differences between NO-releasing and relative controls are indicated at p 
< 0.05 (*).At 6 weeks, the TP-470 topcoated 18 mg/mL AEAP3 nanoparticle system was not tested 
due to low sample size (n = 2). Data are mean ± standard error of the mean. 
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identical NO payloads further stresses the need to extend NO release to achieve the most 
desirable FBR. At 1 week, only the 36 mg/mL MPTMS nanoparticle system, releasing the 
greatest NO flux over this length of time, showed a statistically significant reduction in the 
inflammatory response, further supporting Gifford’s observations. 
 In contrast, the chronic inflammatory response was largely unaffected by NO release 
in this study as no NO-releasing substrate was capable of mitigating the inflammatory 
response at 3 or 6 weeks of implantation (Fig. 3.5.C and 3.5.D). At 6 weeks, the 36 mg/mL 
MPTMS nanoparticle system resulted in an apparent 22% reduction in the inflammatory 
response (0.05 < p < 0.10). Such results are contradictory to a previously reported short-term  
(72 h) NO-releasing xerogel system that improved the chronic inflammatory response,
25
 but 
are in good agreement with the Gifford et al. study where the inflammatory response was 
mitigated only during active NO release from the implant.
27
 It is important to note previous 
experiments by Gifford et al. and Hetrick et al. were performed in rodent models that may 
not be as quantitatively relevant to humans as porcine models.
25, 27, 30
 
 3.4. Conclusions 
 These results stress the need to examine NO release kinetics in the development of 
implantable materials. Furthermore, there is a need to create materials with NO release 
durations exceeding two weeks, specifically in relation to mitigating the inflammatory 
response. Approaches for enhancing NO release durations include increasing the 
hydrophobicity of the polymer matrix or making use of longer releasing S-nitrosothiol NO 
donors (e.g., tertiary S-nitrosothiols). Of course, such changes may affect glucose sensor 
response/performance. Although the mitigation of the FBR observed in our study may prove 
beneficial for indwelling glucose sensors, the effects of NO release should also be evaluated 
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for percutaneous implants to confirm if the same degree of tissue integration is achieved. 
Studies evaluating the effects of NO release on the performance of percutaneous implants are 
currently underway in our lab. 
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Chapter 4: 
Nitric oxide-flux dependent adhesion and viability of bacteria  
to fibrinogen-adsorbed surfaces 
4.1. Introduction 
 Implanted medical devices and materials are increasingly used in hospitals to treat 
and/or monitor a multitude of health problems. While some devices are implanted for days 
(e.g., catheters), others may reside in a patient’s body for years (e.g., orthopedic implants). 
Regardless of time implanted, device-associated infections are a problem for many of these 
medical implants.
1
 For example, central venous catheters (CVCs) result in ~80,000 
bloodstream infections annually, extending the patient’s hospital stay while requiring 
rigorous and expensive treatment.
2, 3
 
 Bacterial adhesion is an important factor for mitigating implant-associated infection 
as bacteria readily adhere to and colonize on medical device surfaces, often leading to 
infection.
4
 Protein adsorption influences subsequent bacterial adhesion.
5
 Once protein 
adsorbs, bacteria adhere to the protein-coated interface, colonizing within 6 h post-
implantation.
6
 Subsequently, bacteria proliferate, eventually depositing an extracellular 
matrix to protect the community of cells, resulting in a biofilm.
7
 Eradication of biofilm 
bacteria requires greater concentrations (up to 1000x) of antibiotics than simple planktonic 
bacteria killing with ineffective treatments resulting in device removal.
8, 9
 Both killing of 
adhered bacteria and prevention of bacterial adhesion have been shown to decrease implant-
associated infections.
4
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 To date, many clinically approved materials do not sufficiently prevent bacterial 
adhesion and biofilm formation.
10
 Development of anti-adhesive and antibacterial surfaces is 
thus important for next generation devices. Two approaches are most common: 1) the 
development of surface coatings that promote passivation (by either reducing protein or 
bacterial adhesion); and/or, 2) biomaterials that actively release an antimicrobial agent.
1
 
Passive materials (e.g., quaternary ammonium-modified interfaces)
11-13
 have a limited sphere 
of influence as they are only able to affect bacteria in direct contact with the biomaterial. 
Often, the efficacy of passive coatings us reduced upon protein adsorption. Materials that 
actively release antimicrobial agents impact bacteria both in contact with and in the vicinity 
of the implant, providing a more robust response to bacteria challenge, particularly if the 
agent is biocidal. Indeed, the release of molecules that inhibit or kill adhered bacteria allow 
for improved device performance and/or longevity. Antimicrobial agents that have been 
effectively loaded into polymeric biomaterials include antibiotics,
14, 15
 antibodies,
16
 silver 
ions,
17
 and nitric oxide (NO),
18, 19
 with each significantly impacting bacterial adhesion and 
adhered bacteria viability. Of these, NO is particularly advantageous due to its central role in 
the immune response to pathogens, localized action/reactivity, and broad-spectrum efficacy. 
Nitric oxide is in fact produced by macrophages to fight bacteria.
20, 21
 
 Materials capable of storing and releasing NO are being developed as coatings to 
limit bacterial adhesion and subsequent infection.
22, 23
 Release of NO from an implanted 
material has been demonstrated to decrease the incidence of bacterial colonization versus 
control materials.
24, 25
 Nablo and Schoenfisch reported that NO fluxes ≥32 pmol cm-2 s-1 
inhibited Pseudomonas aeruginosa adhesion by 85%.
19
 Charville et al. subsequently 
examined the NO flux-induced reduction of bacterial adhesion in the presence of adsorbed 
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fibrinogen (Fg) to better mimic in vivo conditions.
18
 Adsorbed fibrinogen actually enhanced 
bacterial adhesion to substrates though NO release still decreased adhesion in a flux-
dependent manner. 
 Along with a reduction in initial bacterial adhesion, NO has the potential to kill 
adhered bacteria since it is a biocidal agent. Nitric oxide release from small molecule and 
macromolecular NO donors has proved efficacious in the eradication of planktonic 
bacteria.
26-29
 The increased killing activity of macromolecular scaffolds was attributed to the 
direct association of such materials with the bacteria, effectively concentrating the NO 
delivery.
26, 29
 Surfaces capable of NO release would deliver a similar concentrated payload to 
adhered bacteria. Hetrick and Schoenfisch previously reported the killing efficacy of NO for 
P. aeruginosa, and demonstrated dose-dependent bactericidal action.
30
 Herein, we 
investigated the NO fluxes necessary to inhibit bacterial adhesion and reduce the viability of 
adhered bacteria as a function of bacteria species. 
4.2. Materials and Methods 
 3-mercaptopropyltrimethoxysilane (MPTMS) was purchased from Gelest 
(Morrisville, PA). Methyltrimethoxysilane (MTMOS), poly(vinyl chloride) (PVC), and 
diethylenetriamine pentaacetic acid (DTPA) were purchased from Fluka (Buchs, 
Switzerland). Human fibrinogen (Fg) was obtained from Enzyme Research Laboratories 
(Southbend, IN). Fibrinogen was stored at -80 °C, thawed at 37 °C for 10 min, and 
maintained at ambient temperature. Staphylococcus aureus (ATCC #29213), methicillin-
resistant Staphylococcus aureus (MRSA; ATCC #33591), Staphylococcus epidermidis 
(ATCC #35983), Enterococcus faecalis (ATCC #29212), Pseudomonas aeruginosa (ATCC 
#19143), and Escherichia coli (ATCC #53323) were obtained from American Type Culture 
95 
 
Collection (Manassas, VA). Nitric oxide was purchased from Praxair (Danbury, CT). Nitric 
oxide calibration gas (26.39 ppm; balance nitrogen), nitrogen, and argon were purchased 
from National Welders (Raleigh, NC). 
 4.2.1. Xerogel synthesis. Xerogels (40% (v/v) MPTMS/MTMOS) were prepared on 
glass slides as previously described by mixing 800 µL ethanol (EtOH), 480 µL MTMOS, 320 
µL MPTMS, and 25 µL hydrochloric acid (HCl; 0.5 M).
31
 The solution was vortexed for 1 h, 
and allowed to age for 4 h at room temperature. Glass microscope slides (9 x 25 mm
2
) were 
sonicated in EtOH for 30 min and dried under a stream of nitrogen. A 30 µL aliquot of the 
xerogel mixture was cast onto each glass slide and dried overnight under ambient conditions, 
then cured in a 70 °C oven for 2 d. The resulting xerogels were stored at room temperature 
until further use. 
 4.2.2. Nitrosation of xerogels. Subsequently, xerogels were nitrosated via incubation 
in 0.5 M HCl containing a 10x molar excess of nitrite (versus moles of thiol) and 100 µM 
DTPA for 3 h.
31
 Of note, xerogels were kept on ice and shielded from light during nitrosation 
to prevent decomposition. Slides were then washed with 100 µM DTPA and stored at -20 °C 
in the dark until further use. Non-nitrosated xerogels were used as control non-NO-releasing 
interfaces. 
 4.2.3. Poly(vinyl chloride) coating. Poly(vinyl chloride) (1.0 g) was dissolved in 
tetrahydrofuran (THF; 10 mL). Approximately 300 µL of the PVC/THF solution was spin-
coated onto control and NO-releasing xerogels using a CHEMAT Technology KW-4A 
Precision Spin-Coater (Northridge, CA) set to spin at 3.0 krpm. The PVC-coated xerogels 
were also stored at -20 °C until further use. 
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 4.2.4. Bacterial adhesion. Bacteria were cultured in tryptic soy broth (TSB) at 37 °C, 
pelleted by centrifugation, rinsed with sterile water, resuspended in a solution of phosphate 
buffered saline (PBS; 10 mM, pH 7.4) with 15% (v/v) glycerol, and stored at -80 °C. 
Secondary cultures were grown from an aliquot of the frozen stock in TSB overnight. A 1 
mL portion of the overnight bacteria was inoculated into 100 mL of TSB and grown to ~10
8
 
colony-forming units (CFU) per mL as measured by optical density. The resulting culture 
was collected by centrifugation (4500 g, 5 min) and resuspended in PBS.  
 To reach the desired NO flux, the PVC-coated NO-releasing xerogels were incubated 
at 37 °C for varying lengths of time from 0.5–96 h. Next, Fg was adsorbed to the PVC-
coated NO-releasing and control xerogel surfaces by incubating the slides in 4 mL of a 20 
µg/mL solution of Fg in PBS (pH 7.4) for 90 min at 37 °C (gentle shaking). The PVC-coated 
xerogels were then removed from the Fg solution and immediately immersed in 4 mL of a 
bacterial suspension (10
8
 CFU/mL) at 37 °C for 60 min. 
 4.2.5. Optical microscopy for imaging of adhered bacteria. Following incubation in 
the bacterial suspension, the xerogels were removed, dipped in H2O to remove loosely 
adhered bacteria, and then dried with a stream of air. Adhered bacteria were imaged via 
phase contrast optical microscopy using a Zeiss Axiovert 200 Inverted Microscope equipped 
with a Zeiss Axiocam at 20x magnification. Three different PVC-coated xerogel slides were 
imaged for each NO flux. Five randomly selected regions on each slide were used to 
calculate an average bacterial surface coverage. The images were digitally processed by 
thresholding to make dark cells contrast sharply with the light background. Percent surface 
coverage was translated from the number of black pixels in the thresholded image and 
normalized relative to controls (i.e., non-NO-releasing) which were scored as 100%. 
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 4.2.6. Adhered bacterial viability. Following adhesion of bacteria to Fg-adsorbed 
PVC-coated xerogels, slides were dipped in sterile H2O to remove any loosely adhered 
bacteria, and then transferred to 4 mL of PBS for incubation for 0, 6, 12, or 24 h. For S. 
aureus, MRSA, S. epidermidis, and E. coli, PBS was supplemented with 0.5% (v/v) TSB to 
ensure viability for 24 h. After incubation, the slides were gently rinsed in sterile H2O. The 
PVC layer was then carefully removed, placed into 1 mL of PBS, and then sonicated for 15 
min at 40 kHz to remove all adhered bacteria.
16, 30
 Removal of bacteria cells via sonication 
was confirmed by optical microscopy of the PVC layer. After sonication, the solution was 
serially diluted and plated onto tryptic soy agar (TSA) nutrient plates. The plates were 
incubated at 37 °C and the bacterial viability was determined by counting the colonies on the 
plates using an IUL Flash & Go (Neutec Group, Farmingdale, NY). The plate counting 
method used herein has an inherent limit of detection of 2.5 × 10
3
 CFU/mL.
32
 
 4.2.7. Contact angle measurements. Static water contact angle measurements of 
fibrinogen-adsorbed PVC-coated, PVC-coated, and bare control and NO-releasing xerogels 
were acquired with a KSV Instruments Cam 200 Optical Contact Angle Meter (Helsinki, 
Finland). 
 4.2.8. Nitric oxide release measurements. Nitric oxide release was measured 
continuously using a Sievers 280i Chemiluminescence Nitric Oxide Analyzer (NOA) 
(Boulder, CO).
33
 Calibration of the NOA was performed by passing ambient air through a 
Sievers NO zero filter and using a 26.39 ppm NO gas (balance N2). For analysis, NO-
releasing xerogels were immersed in 30 mL of deoxygenated PBS shielded from light and 
released NO was carried to the analyzer in a nitrogen stream (200 mL min
−1
). Temperature 
control was maintained using a water bath at 37 °C. 
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4.3. Results and Discussion 
 4.3.1. Material characterization. S-Nitrosothiol NO-donor-modified xerogels
31
 were 
chosen for study to enable investigation of a large range of NO surface fluxes. Indeed, S-
nitrosothiols provide longer NO-release kinetics compared to N-diazeniumdiolate NO donors 
when incorporated into xerogel films.
19, 31, 34, 35
 The desired NO release flux was achieved by 
pre-incubating the xerogels at 37 °C for varying lengths of time. To control for deviations in 
the contact angles of the non-nitrosated and nitrosated xerogels (70 ± 1 and 54 ± 3°, 
respectively), and potentially varied bacterial adhesion,
31
 a PVC topcoat was applied on top 
of the xerogels. The contact angles for controls and NO-releasing xerogels were the same 
(~89 ± 4°) after PVC-modification, as expected. Neither delamination nor degradation of the 
PVC or xerogel layers was observed for the PVC-coated xerogels. 
 Initial experiments revealed that several species (e.g., S. aureus, MRSA, and E. coli) 
did not readily adhere to control PVC-coated substrates (<10% surface coverage). Low 
absolute adhesion for these strains would make accurate measurements of the relative 
adhesion to NO-releasing substrates difficult due to the error inherent with optical 
microscopy evaluation. To enhance bacterial adhesion as well as better mimic in vivo 
biofouling, PVC-coated slides were incubated in fibrinogen (Fg) prior to bacteria exposure. 
Contact angles of the Fg-adsorbed PVC-coated control and NO-releasing xerogels were both 
55 ± 5° (decreased from 89°), confirming Fg adsorption to the PVC-coating altered the 
surface characteristics. Charville et al. previously reported that Fg adsorbs equally to NO-
releasing and control PVC-coated xerogels.
18
 Soaking the Fg-adsorbed surfaces in PBS for 
24 h had no effect on the contact angle. 
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 The NO-release properties of the bare and PVC-coated S-nitrosothiol xerogels are 
provided in Table 4.1. As expected, the PVC topcoat did not significantly alter the NO-
release properties of the xerogels since the NO release is thermally triggered. The xerogels 
released NO up to 14 d at low NO fluxes (e.g., 0.16 pmol cm
-2
 s
-1
 at 14 d). Average NO 
fluxes used in the bacteria studies ranged from 0.5–50 pmol cm-2 s-1, with 50 pmol cm-2 s-1 
selected as the largest flux due to natural loss of NO during the pre-incubation of the xerogels 
in Fg prior to bacteria exposure. Before incubation, the PVC-coated NO-releasing xerogels 
reached a maximum NO flux of 260 pmol cm
-2
 s
-1
 (Table 4.1). The NO flux changes by a 
large degree initially due to the pseudo first-order NO-release kinetics commonly observed 
for S-nitrosothiol-modified xerogels,
31
 so significant NO is lost even during this relatively 
short incubation period. 
 4.3.2. Bacterial adhesion. The degree of bacterial adhesion to PVC-coated control 
and NO-releasing xerogels was examined at large bacteria concentrations (~10
8
 CFU/mL). 
Although such concentrations are not biologically relevant for most implants, a starting 
concentration of ~10
8 
CFU/mL of bacteria allowed for larger absolute surface coverage for 
all bacterial strains, a requirement for observing differences in bacterial adhesion via optical 
microscopy. Using the NO-release data provided in Table 4.1, nitrosothiol xerogels were pre-
incubated at 37 °C for periods between 30 min and 4 d to achieve a wide-range of average 
NO fluxes over a subsequent 1 h bacteria assay (0.50 ± 0.08, 1.0 ± 0.1, 2.5 ± 0.4, 5.0 ± 0.8, 
10 ± 2, 20 ± 4, 35 ± 5, and 50 ± 10 pmol cm
-2
 s
-1
). The resulting NO fluxes allowed for 
careful investigation of NO’s anti- bacterial adhesion properties. Increased error was noted 
for the larger NO fluxes due to the pseudo first-order NO-release kinetics that rapidly change 
at early time points (e.g., NO flux is reduced by >50% between 1 and 5 h). 
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Table 4.1. Nitric oxide-release properties of bare and PVC-coated 40% MPTMS/MTMOS 
xerogels. Data are mean ± standard deviation. 
NO-release properties 
40% MPTMS/MTMOS 
xerogel 
PVC-coated 40% 
MPTMS/MTMOS xerogel 
tmax (min)  1.1 ± 0.2 1.2 ± 0.2 
[NO]max (pmol cm
-2
 s
-1
) 290 ± 70 260 ± 60 
[NO]1 h (pmol cm
-2
 s
-1
) 64 ± 10 58 ± 8 
[NO]5 h (pmol cm
-2
 s
-1
) 26 ± 5 22 ± 4 
[NO]12 h (pmol cm
-2
 s
-1
) 9 ± 1 8 ± 1 
[NO]24 h (pmol cm
-2
 s
-1
) 3.4 ± 0.5 3.2 ± 0.5 
[NO]48 h (pmol cm
-2
 s
-1
) 1.2 ± 0.1 1.1 ± 0.1 
[NO]96 h (pmol cm
-2
 s
-1
) 0.5 ± 0.1 0.5 ± 0.1 
Total NO (µmol cm
-2
) 2.6 ± 0.4 2.5 ± 0.3 
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 Prior to investigating the anti-adhesion properties of NO, we hypothesized a negative 
correlation between adhesion and NO flux would be observed for all strains of bacteria. 
Indeed, a NO flux-dependent decrease in bacterial adhesion was observed for all six bacterial 
strains investigated (Figure 4.1). Of note, the bacterial adhesion is relative to controls with 
100% indicating identical amounts to the control substrates. Four of the strains (S. aureus, 
MRSA, E. faecalis, and E. coli) showed a large susceptibility to NO from 0–20 pmol cm-2 s-1 
with little to no additional reduction in bacterial surface coverage at increased NO fluxes. 
This maximum plateau in reduced adhesion corroborates a previous study by Nablo and 
Schoenfisch where NO release resulted in a large initial reduction in bacterial adhesion but 
was followed by little additional effect beyond some threshold.
19
 In contrast, inhibition of P. 
aeruginosa and S. epidermidis by 50% (20 and 35 pmol cm
-2
 s
-1
, respectively) and 80% (35 
and 50 pmol cm
-2
 s
-1
, respectively) required larger NO fluxes than other strains. While 
greater NO fluxes were necessary to reduce adhesion for these particular strains, the NO 
release still decreased adhesion by >80%, analogous to the relative inhibition for other strains 
(Table 4.2).  
 Linear regressions of the relative bacteria surface coverage as a function of NO flux 
were performed from 0–20 pmol cm-2 s-1 to compare the relative susceptibility of each 
bacterial strain to NO (Table 4.2). This range was chosen as all of the bacteria strains showed 
good linearity (r
2
 = 0.91–0.98), allowing for direct comparison between strains. Five of the 
strains had similar linear regression slopes, ranging from -3.6 to -4.3. Slight variations in 
slope were independent of the class of bacteria (Gram-positive or Gram-negative) and are 
likely an attribute of the broad-spectrum activity of NO arising from multiple mechanisms of 
biocidal action (e.g., nitrosative and oxidative stress).
36
 One exception was S. epidermidis,  
102 
 
 
Figure 4.1. The NO flux-dependent relative adhesion of A) S. aureus, B) MRSA, C) S. 
epidermidis, D) E. faecalis, E) E. coli, and F) P. aeruginosa to Fg-adsorbed PVC-coated 
xerogels. A relative adhesion of 100% represents the adhesion of the strain to control (i.e., 
non-NO-releasing) substrates. Data are mean ± standard deviation. 
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Table 4.2. Linear regression analysis and NO flux required to inhibit adhesion of each 
bacteria strain by 50 and 80% relative to control (i.e., non-NO-releasing) surfaces. Data are 
mean ± standard deviation. 
Bacteria strain 
Gram 
class 
Linear 
regression 
slope
a
 r
2
 
NO flux required to 
reduce adhesion by 
50% (pmol cm
-2
 s
-1
) 
NO flux required to 
reduce adhesion by 
80% (pmol cm
-2
 s
-1
) 
S. aureus + -4.3 ± 0.5 0.922 10 20 
MRSA  + -3.7 ± 0.5 0.914 10 20 
S. epidermidis + -1.7 ± 0.2 0.939 35 50 
E. faecalis + -4.3 ± 0.4 0.954 10 20 
E. coli - -4.0 ± 0.4 0.953 10 20 
P. aeruginosa - -3.6 ± 0.3 0.984 20 35 
 
a
Slopes calculated from NO fluxes between 0–20 pmol cm-2 s-1 
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the only bacterium with a relatively low susceptibility to NO with respect to bacterial 
adhesion (slope of ~1.7). Charville et al. observed a similar phenomenon while investigating 
the role of Fg and NO release on bacterial adhesion.
18
 S. epidermidis is unique in that it has 
Fg-binding proteins, such as serine-aspartate repeat G (SdrG), present on its surface.
37
 While 
S. aureus strains also have Fg-binding proteins (e.g., Clumping Factor A),
38
 the dissociation 
constant (KD) of SdrG is two orders of magnitude lower than Clumping Factor A, indicating 
a significantly increased binding strength.
39
 The large affinity of SdrG to Fg likely decreases 
the susceptibility of S. epidermidis to the anti-adhesive effects of surface-derived NO. 
Despite the relatively low efficacy of NO in preventing adhesion of S. epidermidis, exposure 
to fluxes >20 pmol cm
-2
 s
-1
 further diminished bacterial surface coverage with an 81% 
reduction in adhesion compared to control surfaces for a flux of 50 pmol cm
-2
 s
-1
. Greater NO 
fluxes may further inhibit S. epidermidis adhesion, however, over the 1 h period the 
maximum average NO flux achieved was limited to 50 pmol cm
-2
 s
-1
 using the S-nitrosothiol-
modified xerogels.   
 4.3.3. Bacteria surface viability. Reduction of bacterial adhesion is an important 
initial step in the design of antibacterial interfaces that prevent colonization on implanted 
materials. However, the most effective antibacterial surfaces should not only reduce bacterial 
adhesion, but also eradicate adhered bacteria to minimize bacteria proliferation and biofilm 
formation.
40
 Previous work with P. aeruginosa demonstrated reduced viability of adhered 
bacteria on a NO-releasing interface in a dose-dependent manner.
30
 However, the previous 
study was limited to P. aeruginosa, and thus the effect of NO release on the viability of 
adhered bacteria was not systematically investigated with respect to bacterial strains. Based  
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on prior literature, we hypothesized that many bacteria species will exhibit reduced viability 
in a NO dose-dependent manner since NO’s actions are broad spectrum. The effect of total 
NO payload (i.e., cumulative NO release) over time was thus investigated against six strains 
of bacteria adhered to Fg-adsorbed PVC-coated xerogels to evaluate the potential for surface-
derived NO to kill biomedically-relevant adhered bacteria. After the 1 h bacterial adhesion 
assay, substrates were incubated in PBS (E. faecalis and P. aeruginosa) or 0.5% TSB in PBS 
(S. aureus, MRSA, S. epidermidis, and E. coli) to provide bacteriostatic conditions for 0, 6, 
12, and 24 h. As not all bacteria survived in PBS for 24 h due to lack of nutrients, 0.5% TSB 
was added to S. aureus, MRSA, S. epidermidis, and E. coli solutions to preserve their 
viability. The time-dependent NO payloads of the various initial average NO fluxes are 
provided in Table 4.3. The initial average NO fluxes from 0.5–50 pmol cm-2 s-1 provided NO 
payloads ranging from 38–1700 nmol cm-2 over 24 h of incubation. The NO release follows 
pseudo first-order kinetics and therefore substrates with an initial average NO flux of 20, 35, 
and 50 pmol cm
-2
 s
-1
 delivered 48, 53, and 77% of their 24 h NO payload in the first 6 h, 
respectively (Table 4.3). In contrast, substrates with lower initial average NO fluxes (0.5 and 
1.0 pmol cm
-2
 s
-1
) from the PVC-coated S-nitrosothiol xerogels delivered their NO payloads 
at a constant rate throughout the 24 h experiment, with only ~25% of the 24 h NO payload 
delivered during the first 6 h. 
 Adhered bacteria were removed from PVC-coated xerogel substrates via sonication, 
plated onto TSA plates, and the resulting colonies were enumerated to quantify viable 
bacteria.
30
 Optical microscopy confirmed that this process (sonication) removed 93–100% of 
bacteria from the Fg-adsorbed PVC-coated substrates, allowing for further determination of 
bacterial viability. To ensure study of only the bacteria adhered to the PVC-coated xerogel 
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Table 4.3. Nitric oxide payloads (nmol cm
-2
) at 6, 12, and 24 h after the 1 h adhesion assay 
for the eight initial average NO fluxes examined. Data are mean ± standard deviation. 
  
NO payload (nmol cm
-2
) 
Initial NO flux        
(pmol cm
-2
 s) 
6 h 12 h 24 h 
0.5 9.5 ± 0.8 19 ± 2 38 ± 2 
1.0 17 ± 2 33 ± 3 66 ± 4 
2.5 40 ± 3 72 ± 5 105 ± 9 
5.0 90 ± 9 140 ± 10 240 ± 20 
10 150 ± 20 250 ± 20 370 ± 20 
20 270 ± 20 410 ± 30 550 ± 50 
35 390 ± 50 560 ± 50 740 ± 60 
50 1300 ± 200 1500 ± 200 1700 ± 200 
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and not to the sides or back of the glass substrates, the outer PVC layer was physically 
removed from the glass slide and sonicated. The relative adhered bacterial viability was 
calculated at each time point (t = 6, 12, or 24 h) by dividing the observed viable bacteria 
concentration by the concentration observed for the same NO-releasing material at t = 0 for a 
given bacteria strain and then multiplying by 100 (Equation 4.1). A viability of 100% would 
thus indicate an identical concentration of live bacteria at a given time point relative to that 
NO-releasing material at t = 0. Of note, bacteria adhered to control substrates exhibited 
minimal death or desorption during the 24 h incubation. 
 We aimed to evaluate the time-dependent killing of bacteria to NO-releasing 
substrates. Bacterial viability and surface coverage were comparable at t = 0 for each NO 
flux versus control materials. For example, S. aureus viability at t = 0 for substrates with an 
initial average flux of 50 pmol cm
-2
 s
-1
 was ~15% that of control substrates, which matches 
closely with the ~10% relative adhesion over 1 h (Figure 4.1). The positive agreement 
between surface coverage and viable bacteria counts immediately following the adhesion 
assay indicates that NO release did not result in significant killing of adhered bacteria during 
the 1 h adhesion assay. 
 The time-dependent viability of bacteria adhered to the NO-releasing surfaces is 
provided in Tables 4.4, 4.5, and 4.6. The reduction in viability of all bacteria exhibited a dose 
dependence to NO. At 6 h, NO-releasing substrates notably reduced viability of adhered 
bacteria of five strains of bacteria (MRSA, S. epidermidis, E. faecalis, E. coli, and P. 
aeruginosa). However, the viability of adhered S. aureus cells experienced minimal 
reductions prior to the 24 h time point (Table 4.6). The delay in reduction of S. aureus 
viability may be due to a minimal NO concentration threshold necessary to induce killing for
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 elative viabilit 
t x   NO 
  
 viable adhered bacteria 
t x   NO 
 viable adhered bacteria 
t     NO  
        
Equation 4.1. Calculation for relative viability of bacteria adhered at t = x (x = 6, 12 or 24 h) 
to a given NO-releasing material ([NO] = 0.5, 1.0, 2.5, 5.0, 10, 20, 35, or 50 pmol cm
-2
 s
-1
). 
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Table 4.4. Relative viability (%) of bacteria adhered to NO-releasing surfaces after 6 h 
incubation in bacteriostatic conditions. A relative viability of 100% represents the viability of 
bacteria adhered at the initial average NO flux at t = 0. Data are mean ± standard error of the 
mean. 
  Initial average NO flux (pmol cm
-2
 s
-1
) 
Bacteria strain 0.5 1.0 2.5 5.0 10 20 35 50 
S. aureus 105 ± 19 106 ± 19 85 ± 17 69 ± 28 61 ± 23 84 ± 31 86 ± 21 87 ± 23 
MRSA 93 ± 28 93 ± 30 46 ± 17 39 ± 12 42 ± 16 46 ± 15 45 ± 18 32 ± 12 
S. epidermidis 118 ± 30 84 ± 21 75 ± 22 101 ± 30 41 ± 18 28 ± 13 25 ± 10 24 ± 8 
E. faecalis 96 ± 3 94 ± 2 42 ± 5 24 ± 7 22 ± 6 27 ± 10 33 ± 10 29 ± 9 
E. coli 116 ± 10 116 ± 15 51 ± 17 21 ± 10 22 ± 8 27 ± 8 17 ± 5 16 ± 4 
P. aeruginosa 92 ± 6 110 ± 15 41 ± 18 20 ± 7 18 ± 6 20 ± 8 6 ± 2 5 ± 0.9 
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Table 4.5. Relative viability (%) of bacteria adhered to NO-releasing surfaces after 12 h 
incubation in bacteriostatic conditions. A relative viability of 100% represents the viability of 
bacteria adhered at the initial average NO flux at t = 0. Data are mean ± standard error of the 
mean. 
  Initial average NO flux (pmol cm
-2
 s
-1
) 
Bacteria strain 0.5 1.0 2.5 5.0 10 20 35 50 
S. aureus 69 ± 6 61 ± 25 65 ± 9 39 ± 9 54 ± 13 56 ± 16 60 ± 15 49 ± 6 
MRSA 75 ± 18 82 ± 26 34 ± 13 34 ± 14 23 ± 8 54 ± 13 28 ± 10 21 ± 6 
S. epidermidis 72 ± 20 75 ± 22 40 ± 15 57 ± 17 34 ± 11 24 ± 9 20 ± 8 20 ± 8 
E. faecalis 91 ± 4 61 ± 10 34 ± 11 20 ± 8 21 ± 7 21 ± 6 16 ± 5 11 ± 3 
E. coli 95 ± 22 73 ± 22 38 ± 13 16 ± 4 14 ± 5 7 ± 2 10 ± 3 8 ± 2 
P. aeruginosa 57 ± 2 46 ± 10 33 ± 5 25 ± 12 16 ± 6 8 ± 2 5 ± 2 4 ± 1 
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Table 4.6. Relative viability (%) of bacteria adhered to NO-releasing surfaces after 24 h 
incubation in bacteriostatic conditions. A relative viability of 100% represents the viability of 
bacteria adhered at the initial average NO flux at t = 0. Data are mean ± standard error of the 
mean. 
  Initial average NO flux (pmol cm
-2
 s
-1
) 
Bacteria strain 0.5 1.0 2.5 5.0 10 20 35 50 
S. aureus 67 ± 17 66 ± 19 69 ± 23 43 ± 16 25 ± 12 38 ± 12 22 ± 7 15 ± 6 
MRSA 66 ± 13 72 ± 18 27 ± 11 25 ± 9 21 ± 6 18 ± 6 19 ± 7 15 ± 4 
S. epidermidis 80 ± 12 80 ± 19 38 ± 12 45 ± 16 34 ± 13 20 ± 8 15 ± 5 14 ± 4 
E. faecalis 83 ± 7 50 ± 20 34 ± 2 21 ± 3 23 ± 2 22 ± 4 13 ± 5 9 ± 3 
E. coli 76 ± 11 36 ± 7 36 ± 8 14 ± 5 11 ± 4 8 ± 3 9 ± 3 5 ± 1 
P. aeruginosa 66 ± 3 34 ± 4 29 ± 11 13 ± 4 14 ± 4 4 ± 1 4 ± 1 2 ± 0.4 
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this strain. S. aureus is known to resist NO via metabolic activities and therefore killing may 
require greater NO concentrations.
41
 The rate of the total NO delivery appears to affect the 
decrease in bacteria viability. For example, the cumulative NO payloads of xerogels with 
initial NO fluxes of 2.5 and 0.5 pmol cm
-2
 s
-1
 are approximately equivalent at 6 and 24 h, 
respectively (38–40 nmol cm-2, Table 4.3). However, the viability of E. faecalis at 6 h to 
surfaces with an initial NO flux of 2.5 pmol cm
-2
 s
-1
 (42 ± 5%) is significantly lower than the 
viability at 24 h to surfaces with an initial NO flux of 0.5 pmol cm
-2
 s
-1
 (83 ± 7%). 
 The NO payloads necessary to decrease the viability of adhered bacteria by 50% and 
80% after 24 h are provided in Table 4.7. Cumulative NO release of 66–240 and 240–1700 
nmol cm
-2
 reduced viability of adhered bacteria by 50 and 80%, respectively (Table 4.7). The 
lowest 24 h NO payload investigated (38 nmol cm
-2
) eradicated 17–34% of adhered bacteria 
for all strains. The maximum reductions in adhered bacteria viability for S. aureus, MRSA, S. 
epidermidis, E. faecalis, E. coli, and P. aeruginosa at 24 h exposure to substrates with an 
initial NO flux of 50 pmol cm
-2
 s
-1
 were 85, 85, 86, 92, 95, and 98%, respectively (Table 4.6). 
Therefore, substrates with an initial NO flux of 50 pmol cm
-2
 s
-1
 delivering a payload of 1.7 
µmol cm
-2
 over 24 h inhibited adhesion of all strains b  !8 % and eradicated ≥85% of the 
adhered bacteria. 
 While the NO payloads employed in the current study were bactericidal to many 
strains, to be used successfully in vivo the materials must avoid cytotoxic effects. Previous 
work by Nablo and Schoenfisch found that materials with an initial NO flux of ~50 pmol cm
-
2
 s
-1
 were only slightly cytotoxic to L929 fiborblasts after 24 h incubation.
42
 Furthermore, even 
greater NO payloads were determined to be only mildly cytotoxic. A study using the same 
MPTMS/MTMOS xerogels capable of delivering larger NO payloads than the current study  
113 
 
Table 4.7. The necessary surface-derived total NO release to decrease adhered bacteria 
viability by 50% and 80% after 24 h incubation. 
  
NO payload necessary to reduce 
adhered bacteria viability by 
50% after 24 h (nmol cm
-2
) 
NO payload necessary to reduce 
adhered bacteria viability by 
80% after 24 h (nmol cm
-2
) 
S. aureus 240 ± 20 1700 ± 200 
MRSA 105 ± 9 550 ± 50 
S. epidermidis 105 ± 9 550 ± 50 
E. faecalis 66 ± 4 740 ± 60 
E. coli 66 ± 4 240 ± 20 
P. aeruginosa 66 ± 4 240 ± 20 
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revealed that NO release reduced adhered L929 fibroblast viability by ~30% over 24 h 
compared to control xerogels.
31
 These previous results reveal that NO fluxes capable of 
greatly reducing bacterial adhesion and viability avoid cytotoxic effects against mammalian 
cells. 
 4.4. Conclusion 
 The adhesion and viability of six bacteria species (S. aureus, MRSA, S. epidermidis, 
E. faecalis, E. coli, and P. aeruginosa) in the presence of adsorbed Fg was reduced at NO-
releasing surfaces. An average NO flux from 20–50 pmol cm-2 s-1 decreased bacterial 
adhesion by >80% for all bacteria over a 1 h exposure. With the exception of S. epidermidis, 
the adhesion of Gram-positive and Gram-negative bacteria were equally affected by surface- 
derived NO release. S. epidermidis required significantly greater NO fluxes to inhibit 
adhesion by >80%, that we hypothesize is due to the affinity of the Fg-binding proteins on 
the cell surface to the adsorbed Fg. In addition to NO influencing general adhesion, it was 
also shown to decrease bacteria viability. Indeed, the number of viable bacteria adhered to 
NO-releasing substrates was decreased after 24 h in a dose-dependent manner by up to 98%  
compared to bacteria viable immediately following adhesion. Future experiments should
optimize the NO concentrations and NO release kinetics to maximize the effects of NO on 
bacterial adhesion and killing. 
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Chapter 5: 
Summary and Future Directions 
5.1. Summary 
 Nitric oxide was shown to directly influence bacterial adhesion and viability as well 
as subcutaneous tissue integration of materials. In Chapter 2, the tissue integration of NO-
releasing materials was quantified temporally through microdialysis. The technique 
quantifies the resistances to mass transfer due to the FBR when using a non-equilibrium, 
steady-state flow rate. Nitric oxide release was imparted to microdialysis probes through the 
use of saturated NO solutions to achieve a constant NO flux of 162 ± 18 pmol cm
-2
 s
-1
. When 
implanted into rat subcutaneous tissue, probes were perfused daily for 8 h, delivering 4.6 ± 5 
µmol cm
-2
 of NO. Recovery of glucose by NO-releasing microdialysis probes was 
significantly greater than control probes at 7 d post-implantation. The recovery of glucose by 
NO-releasing probes was constant over the 14 d implantation period. Histological analysis of 
the adjacent tissue revealed a decreased collagen capsule thickness and reduced 
inflammation. These observations may account for the significant improvement in glucose 
recovery and further support the effect of NO in improving tissue integration. 
 In Chapter 3, investigations on the roles of both NO release kinetics and payloads on 
the tissue integration of materials with dimensions similar to implantable glucose sensors 
were detailed. Stainless steel wires were coated with NO donor-doped polyurethane. Nitric 
oxide donors were used to achieve varying NO release kinetics including small molecules 
(i.e., PROLI/NO), N-diazeniumdiolate nanoparticles (i.e., AEAP3/TMOS), and S-nitrosothiol 
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nanoparticles (i.e., MPTMS/TEOS). To further alter NO release kinetics, polyurethanes of 
varying hydrophobicity were coated onto the NO donor-doped polyurethane. The 
hydrophobic polymer topcoats were confirmed to slow the NO release from N-
diazeniumdiolate NO donors. Collectively, these strategies allowed us to vary the total NO 
payloads from ~2.7–9.3 µmol cm-2, the maximum NO fluxes from 41.8–3128 pmol cm-2 s-1, 
and the NO release durations from 6 h–14 d. Histological analysis revealed that extended NO 
release kinetics correlated with reduced capsule thickness. Substrates with the longest NO 
release duration (i.e., 14 d) and greatest NO payload (i.e., 9.3 µmol cm
-2
) resulted in the 
largest reduction in capsule thickness (i.e., ~75%) at both 3 and 6 weeks of implantation. 
Though these substrates most significantly impacted collagen capsule thickness, they also 
increased collagen density in the capsule that may act to impede glucose diffusion. 
Inflammatory cell counts were only affected while substrates were still releasing NO. 
Therefore, differences were only observed at 3 and 7 d as none of the substrates were 
releasing NO after 2 weeks. These results illustrate the necessity for large NO payloads and 
long release kinetics to maximally enhance the tissue integration of subcutaneous implants. 
 While the focus of Chapters 2 and 3 was to evaluate the effects of NO on the FBR, 
NO’s influence on bacterial colonization, and specifically its ability to prevent adhesion and 
viability, were described in Chapter 4. S-nitrosothiol xerogels were utilized for these studies 
due to their ability to produce long and constant NO release, a necessity for complete 
evaluation of the effect of flux on bacterial adhesion. To provide reproducible interfaces for 
the bacteria to adhere to and eliminate any differences based on contact angle, a PVC layer 
was spin-coated onto the xerogels. Furthermore, substrates were incubated with fibrinogen 
prior to adhesion thus enhancing bacterial affinity for the substrates to better simulate the in 
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vivo environment and enhance bacterial adhesion. These experiments revealed that fluxes of 
20–50 pmol cm-2 s-1 resulted in >80% reduction in adhesion for bacterial strains tested. To 
evaluate the effect of NO on adhered bacteria, the viability was quantified at 0, 6, 12, and 24 
h post-adhesion. The adhered bacterial viability showed NO dose-dependent behavior, with 
large NO payloads (1.7 µmol cm
-2
) eradicating ≥85% of adhered bacteria after 24 h 
incubation in bacteriostatic conditions. 
5.2. Future Directions 
 While a direct effect of NO on the FBR was observed, the ability of NO release to 
enhance sensor performance in subcutaneous tissue remains uncertain. A thinner collagen 
capsule and decreased inflammatory response should decrease lag time and sensor 
attenuation,
1
 but only in vivo experiments will confirm this. The NO donor-doped 
polyurethanes could be employed as glucose sensor membranes to achieve variable NO-
release kinetics and payloads, and careful investigation of NO-releasing glucose sensors in 
vivo should be conducted to evaluate any benefit of the observed tissue integration on sensor 
performance. It is also important to note that the FBR may be different for percutaneous 
compared implants (versus subcutaneous) due to external forces.
2, 3
 Though histological 
differences and increased glucose recovery were achieved with percutaneous NO-releasing 
microdialysis probes, these probes may have benefited from large NO fluxes from daily 
perfusion of saturated NO solutions. Studies examining the differential tissue integration of 
substrates implanted percutaneously versus purely subcutaneously with identical NO-release 
properties should be investigated next. 
 While NO release was shown to enhance tissue integration (Chapter 3), the molecular 
mechanisms responsible remain poorly understood. In vitro cell culture is one method for 
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investigating the cellular responses to NO-releasing materials. In this way, materials could be 
exposed to NO-releasing small molecules, dendrimers, nanoparticles, or surfaces and their 
cytokine expression (e.g., vascular endothelial growth factor) studied as a function of NO 
flux and duration. Similar to experiments in Chapter 4, the NO flux-dependent 
adhesion/behavior of mammalian cells to NO-releasing surfaces should be studied. Nablo et 
al. previously examined the adhesion and morphology of L929 fibroblasts to 
AHAP/BTMOS-based NO-releasing xerogels.
4
 Future studies should examine the effects of 
NO release on cell expression of fibroblasts and other inflammatory cells (e.g., 
macrophages). Furthermore, it is known that the development of foreign body giant cells 
(FBGCs) can negatively impact the performance and stability of implanted devices.
5
 The 
development of FBGCs has been previously examined in vitro over time upon exposure to 
cytokines (e.g., interleukin 4).
6, 7
 In this manner, the effect of NO-releasing surfaces on the 
development of FBGCs could also be studied. 
 While in vitro cell culture is generally a cost-effective and simple way to test 
materials, the FBR is not fully represented in vitro. Investigations of the molecular response 
in vivo has been studied using a cage implant system, first described by Marchant and 
coworkers.
8
 This in vivo method allows for testing of tissue response to biomaterials through 
either the quantification and characterization of inflammatory cells and/or by evaluation of 
cytokines present in the exudates.
9
 This method also provides temporal information without 
premature sacrifice of the animal. Upon explantation of the cage, the extent of foreign body 
giant cell formation may be quantified. These giant cells contribute reactive oxygen species 
that at times degrade polymer membranes.
5
 In this manner, the mechanisms in which NO 
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release enhances tissue integration can be more thoroughly understood when exposed under 
vivo conditions. 
 Investigations on the biocompatibility of glucose sensors are often tested in healthy 
animals, though the sensors are designed for diabetic patients. It is well known that diabetics 
suffer from diminished wound-healing capabilities.
10
 Measurements of nitrite and nitrate by 
Schaeffer et al. indicate, at least indirectly, that wound NO concentrations in diabetic animals 
are significantly depressed compared to controls.
11, 12
 Even when hyperglycemia is controlled 
to normoglycemic concentrations, these concentrations are significantly depressed.
12
 The 
lack of NO produced in the wound environment may contribute to the diminished healing 
capacity in diabetic patients. Indeed, investigations found that the administration of NO to 
diabetic wounds in mice was more effective in enhancing wound healing compared to 
controls.
13
 For these reasons, testing of tissue compatibility for NO-releasing materials in 
diabetic animals is essential. It is possible that the enhancements in tissue integration via NO 
release will be more pronounced in diabetic animals, while other potential strategies (e.g., 
porosity, VEGF) may not provide as drastic results. 
 Lastly, the effects of NO-mediated bacterial adhesion and viability were investigated 
in Chapter 4. While the data were promising with respect to indentifying an optimal NO flux, 
the ability to prevent adhesion and viability in vivo will provide better insight into the ability 
of NO to affect bacterial colonization. For example, while silver treatments are capable of 
reducing bacterial viability in vitro, in vivo tests often do not achieve such results.
14
 Our lab 
has previously examined the ability of AHAP3/BTMOS-based NO-releasing xerogels to 
reduce bacterial colonization to orthopedic implants in rats.
15
 This study only examined the 
antibacterial performance of one NO flux (to impede bacterial colonization), and may not 
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represent the optimal NO release. Future studies should examine in vivo antibacterial 
behavior as a function of NO flux and duration. As previously noted, the primary focus of 
this work is to develop more compatible glucose sensors for diabetic patients, which suffer 
from diminished healing.
10
 Therefore, materials found to be suitable for decreasing bacterial 
adhesion and viability should be examined in diabetic models as these are more susceptible 
to infection compared to healthy (i.e., non-diabetic) subjects. It may be that the apparent lack 
of NO in diabetic animals will greatly benefit from NO release and therefore inhibit bacterial 
colonization at the implant site. 
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